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The Regulation and Role of Hypoxia Inducible Factor-1 (HIF-1) in
Human Cancer
Heath Devin Skinner

ABSTRACT
Hypoxia inducible factor-1 is a heterodimeric basic-loop-helix transcription factor
composed of two subunits, HIF-1α and HIF-1β. HIF-1β is constitutively expressed in cells,
while HIF-1α is upregulated by hypoxia as well as growth factors and oncogenes. In this study
we focus on the regulation of HIF-1α expression by phosphatidylinositol-3 kinase (PI3K), and
novel functions of HIF-1α. Chapter 1 of this dissertation, consists of background and a brief
review of the literature regarding PI3K signaling and HIF-1α . Chapter 2 focuses on the
observation that basal HIF-1α expression is upregulated in ovarian cancer and the mechanism by
which PI3K regulates this effect. Chapter 3 show the results of inhibition of HIF-1α using small
interfering RNA (siRNA) in several in vivo models of ovarian cancer. Chapter 4 presents data
showing that manipulation of HIF-1α expression affects cancer cell sensitivity to common
chemotherapeutic agents. Chapter 5 discusses a novel target of HIF-1, cyclooxygenase-2. In
chapter 6, we present the overall summary and conclusions of this dissertation.
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I. Phosphatidylinositol 3-kinase (PI3K) signaling
Phosphatidylinositol-3 kinases (PI3Ks) phosphorylate the D3 position of the inositol ring in
phosphoinositides (118). Several members of this family are known, however the only member
directly linked to carcinogenesis are Class IA PI3K which are usually activated by receptor
tyrosine kinases (3). PI3K is a heterodimer consisting of two subunits, a regulatory subunit, p85,
and a catalytic subunit, p110 (28,40,45,55). Activation of PI3K normally occurs via interaction
with the regulatory subunit; however it has been shown that Ras can directly bind and activate
the p110 catalytic subunit(87). Once activated, PI3K leads to the generation of
phosphatidylinositol (3,4,5) trisphosphate (PIP3) which recruits Akt, a serine/threonine kinase, to
the plasma membrane. The activity of PI3K is opposed by the lipid phosphatase PTEN which
preferentially removes a phosphate group from the D3 position (68,120). PIP3 also recruits
phosphatidylinositol dependent kinase-1 (PDK1) to the plasma membrane (2,31). PDK1 then
phosphorylates Akt at Thr 308 leading to its activation (1,104). After being phosphorylated, Akt
activates a series of down stream targets including: NF-κB (52,79,88), BAD (26), FHTF (73,86),
glycogen synthase kinase-3β (24) and the mammmalin target of rapamycin (mTOR) (14,93).
II. PI3K and cancer
Recently it has been shown that PI3K plays an important role in cancer. The first
evidence of the importance of PI3K in cancer was the finding that an avian virus known to cause
hemangiosarcoma in chickens, AV-16, encoded an active form of the catalytic domain of PI3K
(18). Later, it was shown that other forms of PI3K are oncogenic due to the activation of Akt
(4,51,56). Other studies have shown that PTEN, an antagonist of PI3K, is inactivated in a large
number of human cancers including: glioblastoma, melanoma, endometrial carcinoma, prostate
cancer, breast carcinoma and ovarian carcinoma (7,29,33,61,64,71,84,101). This is the most
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common cause of PI3K activation in cancer, however in ovarian carcinoma, PI3CA, the gene that
encodes the catalytic subunit of PI3K, is increased in copy number in about 40% of cases (98).
Also, the p85α regulatory subunit of PI3K is often mutated in primary ovarian cancer cells (83).
Furthermore, two isoforms of Akt, Akt 1 and Akt2, are activated in a large number of ovarian
carcinomas (106,122).
One of the mechanisms by which PI3K stimulates tumorigenesis is via the regulation of
new blood vessel formation or angiogenesis. Direct inhibition of PI3K as well as expression of
functional PTEN leads to decreased synthesis of vascular endothelial growth factor (VEGF) and
decreased angiogenesis (50,77). Constitutively activation of either PI3K or Akt has the opposite
effect (50). Furthermore, PI3CA null mouse embryos exhibit defective angiogenesis (8).
Finally, forced expression of wild type PTEN in cancer has been shown to decrease both tumor
growth and angiogenesis (57,117).
III. PI3K/Akt and HIF-1α
Recently it has been shown by our group and others that the PI3K/Akt signaling cascade can
regulate HIF-1α expression (48,72). Hypoxia inducible factor-1 (HIF-1) is a heterodimeric basic
helix-loop-helix transcription factor composed of two subunits, HIF-1α and HIF-1β (49,114).
Because HIF-1β is constitutively expressed in human cells, the transcriptional activity of HIF-1
is regulated by the level of HIF-1α. Inhibition of PI3K signaling has been shown to inhibit HIF1α expression in response to a variety of different stimuli, including hypoxia, growth factors and
oncogenes (48,80,90,102). This inhibitory effect can be reversed by forced expression of Akt
(111) PTEN has also been shown to regulate HIF-1α expression (48,128).

Under normoxic

conditions within the cell, HIF-1α is hydroxylated by a family of prolyl hydroxylases on Pro402
and Pro564 within a region of HIF-1α known as the oxygen dependent degredation domain
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(ODDD) (17,46,47). This allows the binding of the E3 ubquitin ligase, von Hippel Lindau
protein (pVHL) to HIF-1α (46,47). After ubquitinylation, HIF-1α is rapidly degraded by the
proteosome, such that the half-life of HIF-1α in normoxia is less than 5 minutes. However, in
hypoxia, prolyl hydroxylase does not function, therefore, pVHL cannot bind and ubquitinylate
HIF-1α (46,47). This stabilizes HIF-1α, allowing it to translocate to the nucleus and bind HIF1β, forming the active transcription factor, HIF-1. After translocation into the nucleus, HIF-1
specifically binds a 5’-RCGTG-3’ hypoxic response element (HRE) present in the promoters of a
number of genes leading to their transcription (96,97). p300/CBP is a required co-factor for
HIF-1 DNA binding. This represents another level of HIF-1 regulation, as a asparaginyl
hydroxylase that hydroxylates HIF-1 at Asn851, dubbed factor inhibiting HIF-1 (FIH), can
abrogate the binding of HIF-1 and p300/CBP, leading to decreased levels of HIF-1
transcriptional activation (100). Genes upregulated by HIF-1 include: iNOS, heme oxygenase1,
erythropoietin, aldolase, several glycolytic enzymes, and vascular endothelial growth factor
(VEGF) (25,34,35,62,63,95,97).
HIF-1α plays a major role in tumor angiogenesis. HIF-1α is over-expressed in both
primary and metastatic human cancer, and is correlated to tumor angiogenesis and
aggressiveness as well as patient mortality (9-11,13,123,126). HIF-1α has also been found to be
overexpressed in tumor biopsies from several different types of cancer along the invading margin
(123,126). Manipulation of HIF-1α expression in tumor xenograft studies has led to conflicting
results. Some studies have shown that inhibition of HIF-1α decreases tumor growth and
angiogenesis, however others have shown that inhibition of HIF-1α has no effect on tumor
angiogenesis (20,89,103). One study even showed that inhibition of HIF-1α led to the generation
of larger tumors (16). Thus, the role of HIF-1α in tumorigenesis has yet to be explained.
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IV. PI3K/HIF-1α and p53/Mdm2 signaling pathways
Discovered in the early 1980’s, p53 is one of the most widely studied tumor suppressor genes.
This protein functions to induce apoptotic cell death in response to a number of oncogenic
stresses and mutations in p53 occur in greater than half of all human cancers (113). Levels of
p53 in the cell are controlled primarily at the post-translational level by the E3 ubquitin ligase,
Mdm2, in a mode of regulation similar to that observed with HIF-1α and pVHL (43,44,59).
Interestingly, Mdm2 transcription is upregulated by p53, forming an auto-regulatory loop to
control the levels of p53 in the cell (119). Recently it has been shown that p53 and Mdm2
interact with the PI3K signaling cascade. Specifically, it has been shown that activated Akt
phosphorylates Mdm2, leading to decreased p53 levels in the cell and decreased p53
transcriptional activity (69,75). HIF-1α has also been shown to interact with p53/Mdm2
signaling. The DNA binding region of p53 has been shown to bind HIF-1α in an in vitro assay
(42). HIF-1α has also been shown to bind Mdm2 leading to increased transcriptional activity
(Agani 2005). Another recent study showed that loss of p53 leads to increased expression of
HIF-1α in the cell (85). However, the exact physiological significance of the interaction
between PI3K, HIF-1α and Mdm2 remains to be elucidated.
V. COX-2 and HIF-1α
Recently it has been shown that cyclooxygenase 2 (COX-2), a dual function peroxidase,
plays a significant role in angiogenesis. Cyclooxygenases are a group of enzymes that convert
arachadonic acid to prostaglandins (PG) such as PGD2 and PGE2 and thromboxane (THX) (39).
COX-2 and HIF-1α have been linked to similar processes in the cell. Both COX-2 and HIF-1α
stimulate cancer cell invasion via MMP activity (23,58,100,107) and promote tumor

-4-

angiogenesis (38,94). Both have been associated with VEGF secretion (38,94) and both are
stimulated by hypoxia, as well as chemical mimetics of hypoxia such as CoCl2 (66,116) and iron
chelators like desferroxamine (109,115). NSAIDs have been shown to inhibit HIF-1α
expression, however this effect was shown to be at least partly COX-2 independent (82,127).
Interestingly, a recent study has shown that PI3K/Akt is an important COX-2-independent target
of celecoxib, a “selective” COX-2 inhibitor, in prostate cancer (60). Specifically, celecoxib
dramatically inhibits PI3K/Akt signaling in the absence of COX-2. This phenomenon could
account for the COX-2 independent inhibitory effect of COX-2 inhibitors on HIF-1α expression.
Previously, some have shown that COX-2 may upregulate HIF-1α expression via PGE2 (65).
However, the exact nature of the interaction between HIF-1α and COX-2 has yet to be
elucidated.
Cyclooxygenases perform two enzymatic functions in the formation of prostaglandins.
Initially, arachadonic acid, found almost exclusively at the 2-position of membrane
phospholipids, is cleaved from the cell membrane by phospholipase A2 (PLA2) to form free
arachadonate (process rev. in (27)). This arachadonate is then oxidized by cyclooxygenase to
form PGG2, an unstable intermediate prostaglandin. This is then converted to PGH2 by the
peroxidase activity of cyclooxygenase. PGH2 is the progenitor of a variety of different
prostaglandins, such as PGE2, as well as thromboxane (TXA). Two cyclooxygenases, dubbed
COX-1 and COX-2, have been described thus far. COX-1 is constitutively expressed in most
tissues and is responsible for maintainence of the mucosa of the gastric lining as well as the
regulation of renal blood flow (27). Conversely, COX-2 is inducible by a variety of different
stimuli including cytokines, growth factors, oncogenes and tumor promoters (27). This property
allows COX-2 to play a significant role in inflammation and malignancy.
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COX-2 affects a variety of different process in tumors including apoptosis, angiogenesis,
invasion and metastasis. Previously it has been shown that COX-2 expression is upregulated in
tumors compared to surrounding tissue (124). Furthermore, inhibition of COX-2 via NSAIDs
and selective inhibitors leads to decreased size and angiogenesis in a variety of tumor xenograft
models (124).
The pro-apoptotic effects of COX-2 inhibition in cancer cells are well established (27).
In many different cancer cell lines, treatment with NSAIDs, as well as with selective COX-2
inhibitors leads to apoptosis (27). The mechanism by which this occurs is not completely
known. COX-2 inhibition has been shown to upregulate Par-4, a prostate specific pro-apoptotic
gene (125), while COX-2 overexpression decreases the expression of caspase-3 (70).
Interestingly, COX-2 also negatively regulates p53 expression to protect against hypoxiainduced apoptosis (67). Conversely, p53 expression can also decrease expression of COX-2
(105).
COX-2 also stimulates cell migration and invasion. COX-2 expression is correlated with
tumor invasiveness in several different types of cancer (76,99,108). Furthermore, treatment with
COX-2 inhibitors decreases cell migration and invasion (5,54,78,107,121). Furthermore, forced
expression of COX-2 increases cell motility and invasiveness in breast cancer cells (100). One
downstream product of COX-2 enzymatic activity, PGE2, has also been shown to stimulate cell
motility and invasion (15,81,110). The mechanism for this effect is disputed, as some data
indicates PGE2 acts via the prostaglandin receptor EP4 and the second messenger cAMP (110),
while others have indicated that PGE2 acts to stimulate cell motility via activation of the
epidermal growth factor receptor (EGFR) and subsequent activation of PI3K/Akt signaling
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(15,81). The stimulatory effect of COX-2 and PGE2 on cell motility and invasion has been
shown to be dependent upon MMP activity (5,54,107) as well as CD 44 (30).
COX-2 is also a potent inducer of angiogenesis. COX-2 expression is correlated with
tumor angiogenesis in clinical samples (19,21,36,37,53). COX-2 inhibitors have been shown to
inhibit angiogenesis via the suppression of secreted pro-angiogeneic factors such as basic
fibroblastic growth factor (bFGF) and VEGF (27). In co-culture with endothelial cells, colon
cancer cells engineered to over-expression COX-2 increased levels of endothelial cell migration
and tube formation (112). Inhibition of COX-2 via NSAID or COX-2 specific-inhibitor has been
shown to decrease angiogenesis in tumor xenograft models (91). Furthermore, it has been shown
that PGE2 stimulates capillary sprouting and angiogenesis (38). Taken together, it seems that
COX-2 plays a strong stimulatory role in angiogenesis.
VI. Significance
All of these signaling proteins play an important role in tumorigenesis and
angiogenesis. Many are upregulated in metastasis and are correlated with patient morbidity and
mortality in clinical studies. Although many of these proteins, such as PI3K and HIF-1α, have
been linked previously, it has yet to be determined how these signaling proteins interact with
HIF-1α. Thus, this study will focus on these interactions as well as novel functions of HIF-1α in
cancer cells.

-7-
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ABSTRACT
Vascular endothelial growth factor (VEGF) expression is elevated in ovarian and other cancer
cells. However, the mechanism that causes this increase in VEGF expression still remains to be
elucidated. In this study, we demonstrated that activation of PI3K signaling mediated VEGF
protein expression at the transcriptional level through hypoxia-inducible factor 1 (HIF-1α)
expression in human ovarian cancer cells. We found that inhibition of PI3K activity by
LY294002 decreased VEGF transcriptional activation, and that forced expression of AKT
completely reversed the inhibitory effect. HDM2 and p70S6K1 are two downstream targets of
AKT that mediate growth factor-induced VEGF transcriptional activation and HIF-1α
expression. We found that inhibition of PI3K by LY294002 inhibited p70S6K1 and HDM2
activity in the cells. Forced expression of p70S6K1 or HDM2 reversed LY294002-inhibited
VEGF transcriptional activation and HIF-1α expression. This study identifies a potential novel
mechanism responsible for increased VEGF expression in ovarian cancer cells. It also indicates
the important role of VEGF and HIF-1 in ovarian tumorigenesis and angiogenesis, which is
mediated by the PI3K/AKT/HDM2 and AKT/p70S6K1 pathways in ovarian cancer cells.
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Introduction
Vascular endothelial growth factor (VEGF) is essential for both physiological and
pathological angiogenesis and has been shown to play a critical role in ovarian cancer. Many
studies have shown that increased VEGF expression correlates with poor prognosis in ovarian
cancer patients (1-3). VEGF is expressed by ovarian cancer cells (4), and is found at high levels
in the malignant ascites of humans as well as in animal tumor models (5-7). Flt-1 and KDR, the
two VEGF receptors, are expressed in both ovarian cancer cells and the ovarian tumor
vasculature (8,9). VEGF production correlates with ovarian cancer cell proliferation (10),
whereas inhibition of VEGF, whether pharmacologically or by an inhibitory antibody, decreases
ascites formation and mortality in ovarian cancer models (11-14).
VEGF is a primary transcriptional target of hypoxia-inducible factor 1
(HIF-1). HIF-1 is a heterodimeric basic helix loop helix transcription factor composed of HIF1α and HIF-1β subunits (15,16). HIF-1β is constitutively expressed in cells, while HIF-1α
expression is upregulated by hypoxia, as well as by a variety of growth factors and oncogenes
(16-23). HIF-1 has previously been shown to play a crucial role in both angiogenesis and tumor
growth (24-27). HIF-1 activity is primarily regulated by the levels of HIF-1α in the cells.
Inhibition of HIF-1α expression leads to decreased tumor size in vivo, while increased HIF-1α
expression has the reverse effect (25-27). In some cancers, HIF-1α expression is associated with
tumor aggressiveness and patient mortality (28-31). Under hypoxic conditions, HIF-1α
expression is controlled primarily at the post-transcriptional level, due to an inability to bind the
E3 ubquitin ligase, von Hippel Lindau protein (pVHL). However, the mechanism of HIF-1α
expression induced by growth factor stimulation has not been completely elucidated. PI3K
signaling was shown to regulate HIF-1α expression in some cell systems in response to growth
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factors and hypoxia (20-23,32,33), while it was shown not to be involved in HIF-1α regulation
in other cell lines (34).
PI3K signaling is frequently upregulated in ovarian cancer cells. PI3CA, the gene that
encodes the p110 catalytic subunit of PI3K, is increased in copy number in 40% of ovarian
cancer occurrences (35). The p85α regulatory subunit of PI3K is also frequently mutated in
ovarian cancer (36). AKT1 and AKT2 are both activated in a large number of ovarian
carcinomas, with activation being associated with a higher tumor stage (37,38). Pharmacologic
inhibition of PI3K decreased ovarian cancer cell proliferation and tumor growth in vivo, and
rendered ovarian cancer cells more sensitive to chemotherapy agents (35,39,40).
In this study, we wanted to determine if PI3K signaling regulates VEGF expression and
transcriptional activation, and to determine whether PI3K-mediated VEGF expression is
regulated by HIF-1α expression in ovarian cancer cells. We further investigated the possible
mechanism by which PI3K signaling mediates VEGF and HIF-1α expression as well as
identified potential signaling molecules for regulating VEGF and HIF-1α expression.

Materials and Methods
Reagents and Cell Culture⎯The human ovarian cancer cell lines A2780, A2780/CP70,
OVCAR-3, and SKOV-3 were maintained in RPMI media supplemented with 10% fetal bovine
serum (Intergen, Purchase, NY), 0.2 units/ml human insulin (Sigma, St. Louis, MO), 2 mM
glutamine, 50 units/ml penicillin, and 50 μg/ml streptomycin (Invitrogen, Carlsbad, CA).
Human umbilical vein endothelial cells (HUVECs) were maintained in EGM Endothelial Cell
medium (Cambrex, East Rutherford, NJ). All cells were cultured at 37°C in a 5% CO2
incubator, and trypsin (0.25%) was used to detach adherent cells for subculture. LY294002 and
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wortmannin were obtained from Calbiochem (La Jolla, CA) and rapamycin was obtained from
Cell Signaling Technology (Beverly, MA).

Immunoblotting Analysis⎯Cells were washed in cold 1x PBS and lysed with RIPA buffer (150
mM NaCl, 100 mM Tris, pH 8.0, 1% Triton X-100, 1% deoxycholic acid, 0.1% SDS, 5 mM
EDTA, and 10 mM NaF) supplemented with 1 mM sodium vanadate, 0.5 mM dithiothreitol
(DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 2 mM leupeptin, 2 mM aprotinin, and 2
mM pepstatin on ice for 30m. Cellular debris was removed by centrifugation at 13,000 rpm for
15 min at 4°C. Total cellular protein concentration was assayed using Bio-Rad® protein assay
reagent (Richmond, CA). Aliquots (40 μg) of protein were loaded onto a SDS/polyacrylamide
gel, and resolved by gel electrophoresis. Proteins were then transferred to a nitrocellulose
membrane in 20 mM Tris-HCl (pH 8.0) with 150 mM glycine and 20% (v/v) methanol.
Membranes were blocked with either 5% nonfat dry milk in 1x TBS or 5% bovine serum
albumin in 1x TBS, and incubated with protein specific antibodies. Proteins were detected via
horseradish-peroxidase conjugated antibodies (NEN, Boston, MA), and visualized through
enhanced chemiluminescence reagent (NEN, Boston, MA).

cDNA Constructs⎯HIF-1α wild type and HIF-1α dominant negative were cloned into the
pCEP4 vector (Invitrogen, Carlsbad, CA) described previously (1). The human VEGF reporter
was constructed by inserting a 2.65 kb KpnI-BssHII fragment of human VEGF gene promoter
into the pGL2-basic vector (Promega, Madison, WI)

(pVEGF-Luc). The pMAP11wt

VEGF reporter was constructed by PCR amplification of a fragment of the VEGF promoter from
–985 to –939. This fragment regulates VEGF transcription in response to hypoxia and contains
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the HIF-1 binding site. The pMAP11mut was constructed by substituting three base pairs in the
HIF-1 binding sequence of the pMAP11wt VEGF reporter. This three base pair substitution
abolishes HIF-1 binding to the region. The β-galactosidase gene driven by the CMV promoter
was used as a control plasmid for transfection efficiency.

Transient Transfection and Luciferase Assays⎯OVCAR-3 cells were seeded in a 6-well plate at
a density of 0.3x 106 cells/well the day before the transfection. The cells were washed twice
with warm Hank’s buffered salt solution (Invitrogen, Carlsbad, CA), and then transfected with
lipofectamine (Sigma, St. Louis, MO) per the manufacturer’s instructions. Briefly, the DNA to
be transfected was incubated with 5 μl/well lipofectamine in serum-free Opti-MEM media
(Invitrogen, Carlsbad, CA) for 30 min. This solution was then added to the cells and allowed to
incubate at 37°C for 4.5 h. The lipofectamine was then removed and cells were cultured as
described above. For the luciferase assays, cells were transfected with VEGF promoter reporter,
and pCMV-β-gal (control). The cells were cultured for 12 h after transfection, followed by
incubation in the absence or presence of LY294002 or rapamycin. At the end of incubation, the
cells were collected in luciferase lysis buffer (Promega, Madison, WI) per the manufacturer’s
instructions. Briefly, 250 μl of luciferase lysis buffer was added to each well and placed at 70°C until frozen. Cells and lysis buffer were allowed to thaw and were then collected and
stored at -70°C until use. Aliquots of protein samples were used for luciferase assay using
luciferase substrate (Promega, Madison, WI), and measured by a monolight luminometer. βgalactosidase (β-gal) activity was determined using 40 μg of cellular protein extracts by the
hydrolysis of o-nitrophenyl-b-D-galactopyranoside at 37°C for 1 h.
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Stable Transfection⎯A2780/CP70 cells were transfected using pcDNA3 vector alone or
pcDNA3-HDM2, which contains a neomycin resistance cassette. The cells were cultured
overnight after transfection, followed by the addition of G418. The G418 resistant cells were
pooled after two weeks and cultured as described above in media supplemented with G418.

VEGF ELISA⎯Media were collected from cells and centrifuged at 800 rpm for 4 min at room
temperature to remove any cellular debris and stored at -70°C. Wells of a 96-well plate were
coated with VEGF polyclonal capture antibodies (R&D Systems, Minneapolis, MN) overnight at
4°C. Aliquots of media were then added to each well and allowed to incubate at room
temperature. VEGF monoclonal detection antibody coupled to horseradish peroxidase (R&D
systems, Minneapolis, MN) was added to the wells and incubated. The wells were washed and
levels of VEGF were detected using 2,2’-Azino-bis(3-ethylbenzathione-6-sulfonic acid [ABTS])
as substrate and 1% H2O2 were then added. The color change was then measured in a 96-well
micro plate reader, and compared to the VEGF standard in the same assay.
Results
The PI3K Inhibitor LY294002 Inhibited VEGF Transcriptional Activation and Protein
Expression in Ovarian Cancer Cells⎯ Increased VEGF expression is an important factor for
inducing ovarian tumorigenesis; however, the mechanism of its elevation still remains to be
elucidated. To determine whether PI3K activity plays a role in VEGF transcriptional activation,
OVCAR-3 cells were transfected with a VEGF promoter reporter containing a 2.6 kb human
VEGF promoter. Inhibition of PI3K activity by LY294002 inhibited the VEGF reporter activity
(Figs. 1A and 1B). This result indicates that PI3K activity is required for VEGF transcriptional
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activation. It is known that VEGF transcription is mainly regulated by HIF-1 in response to
hypoxia. To test whether the HIF-1 binding site at the VEGF promoter is important for PI3Kmediated VEGF transcriptional activation, we constructed a VEGF reporter containing a
functional promoter fragment with the HIF-1 binding site. Inhibition of PI3K by LY294002 also
inhibited the VEGF reporter in a time- and dose-dependent manner (Fig. 1C and 1D). Mutation
of the HIF-1 binding site abolished the inhibitory effect of LY294002 on VEGF transcriptional
activity (Fig. 1E). Thus, the inhibitory effect of LY294002 on VEGF transcriptional activation
requires the HIF-1 binding site at the VEGF promoter. To determine whether LY294002
treatment affects VEGF protein levels, OVCAR-3 and A2780/CP70 cells were treated with
LY294002. A2780/CP70 cells contain the lost function of p53 protein, which would test the
effect of PI3K inhibition without p53 activity in the cells. The VEGF protein levels in the
medium were measured by ELISA. As shown in Figs. 1F and 1G, LY294002 treatment
significantly decreased VEGF protein levels in both cell lines.

LY294002-inhibited VEGF transcriptional activation was reversed by HIF-1α⎯ To further
study whether the inhibitory effect of LY294002 on VEGF transcriptional activation depends on
HIF-1α expression, the cells were co-transfected with VEGF promoter reporters and HIF-1α
plasmids. Transfection with HIF-1α alone significantly increased the VEGF reporter activity,
completely reversed LY294002-inhibited VEGF transcriptional activation and resulted in even
higher levels of activity (Fig. 2A). This result shows that HIF-1α is sufficient to induce VEGF
transcriptional activation in the cells. To test whether HIF-1 activity is required for the VEGF
expression, the cells were transfected with HIF-1α dominant negative construct, which inhibited
the VEGF promoter activity in a dose dependent manner (Fig. 2B). The inhibition was not
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affected significantly by combined treatment with LY294002 and the HIF-1 dominant negative
construct (Fig. 2B). These results suggest that LY294002-inhibited VEGF transcriptional
activation depends on HIF-1α expression.

HIF-1α Protein Expression in Ovarian Cancer Cells Required PI3K Activity⎯To determine
whether HIF-1α expression is mediated by PI3K in ovarian cancer cells, HIF-1α protein levels
were measured in several ovarian cancer cells in the absence or presence of LY294002. HIF-1α
protein levels in human endothelial cells (HUVEC) were used as a negative control. HIF-1α
expression levels in all ovarian cancer cell lines were much higher than those in HUVEC cells
(Fig. 3A). LY294002 treatment specifically inhibited HIF-1α, but not HIF-1β expression,
indicating that HIF-1α expression in these cells required PI3K activation. To determine whether
PI3K is required for growth factor-induced HIF-1α expression, the cells were cultured in serumfree medium for 24 h, followed by the addition of 10% serum, insulin, or IGF-1. Treatment with
serum, insulin, or IGF-1 greatly increased HIF-1α expression in OVCAR-3, A2780/CP70, and
A2780 cell lines, and the induced HIF-1α expression was inhibited by LY294002 (Figs. 3B and
3C). Due to the high basal level in SKOV-3 cells, HIF-1α expression was not induced by IGF-1,
but induced by insulin (Fig. 3C). Both the basal level and induced HIF-1α expression were
inhibited by LY294002 treatment. These data further confirm that PI3K mediates VEGF
transcriptional activation through HIF-1α, but not HIF-1β levels in the ovarian cancer cells with
different properties.

AKT is Essential for PI3K-mediated VEGF Transcriptional Activation⎯AKT is a known target
of PI3K. To confirm that AKT was activated by serum and inhibited by LY294002 in the
- 16 -

ovarian cancer cells, the cells were cultured in serum-free medium for 24 h, pretreated with
LY294002 for 30 min, and then stimulated by serum for 1.5 h. AKT activation, indicated by its
protein phosphorylation, was increased by serum stimulation and inhibited by LY294002 (Fig.
4A). To determine whether expression of active form of AKT is sufficient to restore LY294002inhibited VEGF transcriptional activation, OVCAR-3 cells were transfected with VEGF reporter
and myristrylated AKT. Transfection of AKT significantly increased VEGF reporter activity
and completely reversed LY294002-inhibited VEGF reporter activity in a dose-dependent
manner (Figs. 4B and 4C). Because the full activation of AKT still requires PI3K activity, the
reporter activity is much lower in the presence of LY294002 than that in the absence of
LY294002 (Fig. 4). This data indicates that AKT is a sufficient target of PI3K for mediating
VEGF expression.

Rapamycin Decreased VEGF Transcriptional Activation and VEGF Protein Production

⎯Rapamycin is a specific inhibitor for mTOR and p70S6K1. To investigate whether rapamycin
inhibited VEGF transcriptional activation, OVCAR-3 cells were transfected with the VEGF
reporter, followed by the treatment with solvent alone or rapamycin. VEGF reporter activity was
decreased by rapamycin treatment in a dose-dependent manner (Figs. 5A and 5B), suggesting
that activation of mTOR and p70S6K1 is involved in VEGF transcriptional activation. To
determine whether rapamycin treatment also inhibited VEGF protein levels in ovarian cancer
cells, the cells were treated with rapamycin and VEGF levels were analyzed by ELISA.
Rapamycin treatment decreased VEGF protein levels in both cell lines in a dose-dependent
manner (Figs. 5C and 5D).
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P70S6K1 Was Sufficient to Reverse LY294002-inhibited VEGF Transcriptional Activation⎯To
test whether expression of an active form of p70S6K1 is sufficient to reverse LY294002inhibited VEGF transcriptional activation, OVCAR-3 cells were transfected with a VEGF
reporter and a constitutively active form of p70S6K1. As shown in Fig. 6, forced expression of
p70S6K1 greatly increased VEGF reporter activity and reversed LY294002-inhibited VEGF
transcriptional activation in a dose-dependent manner. These data indicate that p70S6K1 is an
important downstream target of PI3K and AKT for inducing VEGF transcriptional activation in
ovarian cancer cells.

Rapamycin Inhibited HIF-1α, but not HIF-1β expression in OVCAR-3 and A2780/CP70
cells⎯To determine whether rapamycin inhibits HIF-1α and HIF-1β expression in response to
growth factor stimulation, OVCAR-3 and A2780/CP70 cells were cultured in serum-free
medium for 24 h, followed by the addition of serum, IGF-1, or insulin. Rapamycin specifically
inhibited HIF-1α but not HIF-1β expression in response to serum, IGF-1, and insulin (Fig. 7).
This result indicates that rapamycin may inhibit VEGF transcriptional activation through a
decrease of HIF-1α expression in the cells.

Inhibition of PI3K Decreased HDM2 Phosphorylation and Expression in Ovarian Cancer
Cells⎯ Previous studies have indicated that Akt may upregulate the function of HDM2 via
phosphorylation (42, 43). To determine whether inhibition of PI3K/Akt by LY294002 affects
HDM2 phosphorylation and protein levels, OVCAR-3 cells were treated with LY294002 and
analyzed by immunoblotting for HDM2 expression. Both HDM2 phosphorylation and protein
expression were inhibited by LY294002 (Fig. 8).
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Forced Expression of HDM2 Reversed LY294002-inhibited VEGF Transcriptional Activation,
VEGF Expression, and HIF-1α Expression⎯ To determine whether HDM2 acts downstream of
PI3K to affect VEGF transcriptional activation, OVCAR-3 cells were transfected with VEGF
reporter and HDM2 plasmids. After the transfection, the cells were incubated in the absence or
presence of LY294002. Forced expression of HDM2 reversed LY294002-inhibited VEGF
reporter activity in a dose-dependent manner (9A), indicating that HDM2 was sufficient to
restore LY294002-inhibited VEGF transcriptional activation. To test whether the HIF-1 binding
site is required for HDM2-mediated VEGF reporter activity, we used the mutant VEGF reporter
at the HIF-1 DNA binding site. Neither LY294002 nor HDM2 affected the mutant VEGF
reporter activity (Fig. 9B), indicating that LY294002 and HDM2 regulate the reporter activity
through HIF-1 binding site.

HDM2 restored LY294002-inhibited VEGF protein production⎯ To study whether HDM2
reversed LY294002-inhibited VEGF protein expression, the cells were transiently tranfected
with vector alone or HDM2, followed by treatment with LY294002. HDM2 partially reversed
the inhibitory effect of LY294002 on VEGF protein levels (Fig. 10). These data indicate that
HDM2 plays an important role in PI3K-mediated VEGF transcriptional activation and VEGF
protein expression.
To determine whether HDM2 restores LY294002-inhibited HIF-1α expression,
A2780/CP70 cells stably expressing HDM2 or vector alone were cultured in serum-free medium,
then treated with 10% serum in the presence or absence of LY294002. Expression of HDM2 in
the cells reversed LY294002-inhibited HIF-1α expression
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(Fig. 11). Taken together, these

results suggest that PI3K and AKT mediate VEGF transcriptional activation through HIF-1α
expression, and that HDM2 and p70S6K1 signaling pathways are two parallel pathways that
mediate this process.

Discussion
It is known that VEGF plays an important role in ovarian tumorigenesis and
angiogenesis. However, the mechanism by which VEGF expression is elevated is not
completely understood. Genes encoding PI3K are frequently amplified in copy number in
ovarian cancer cells, leading to activation of PI3K signaling (35,36). In this study, we showed
that VEGF protein expression and transcriptional activation were induced by PI3K activation in
ovarian cancer. To understand the mechanism of the observed increased VEGF expression, we
found that PI3K signaling upregulated VEGF expression through HIF-1α. VEGF and HIF-1 are
known to increase tumor growth and angiogenesis. Thus, PI3K may increase ovarian tumor
growth and angiogenesis through VEGF and HIF-1 expression.
To identify the downstream mediators of PI3K necessary for regulating HIF-1α and
VEGF expression in ovarian cancer cells, we investigated potential downstream targets of PI3K
in response to growth factor stimulation. We found that AKT was essential for VEGF
transcriptional activation in the cells. In this study, we were particularly interested in the
downstream targets of AKT that mediate VEGF transcriptional activation in ovarian cancer cells.
We found that p70S6K1 and HDM2 are two parallel pathways that mediate growth factorinduced VEGF transcriptional activation and HIF-1α expression. These results are consistent
with recent studies demonstrating that AKT activation increased HDM2 phosphorylation and its
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activity (41,42). These results may provide useful information regarding VEGF and HIF-1
regulation in other human cancer cells.
Overall, these results identify a novel mechanism by which the observed PI3K activation
and other oncogenic signals in ovarian cancer cells may increase VEGF expression, which in
turn induces angiogenesis and tumor growth. We have identified several members of this
signaling cascade including AKT, HDM2, and p70S6K1 that are necessary for VEGF
transcriptional activation and HIF-1α expression. This study may also provide useful
information and potential targets for anti-ovarian cancer therapy in the future.
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Figure 1. The effects of PI3K inhibitor LY294002 on VEGF transcriptional activation and
VEGF protein level. A and B, OVCAR-3 cells were seeded at 0.5x 106 cells/well on a 6-well
plate the day before the transfection. To test VEGF transcriptional activation, the cells were cotransfected with pCMV-β-gal plasmid and a VEGF reporter containing a 2.6 kb human VEGF
promoter fragment in the pGL2 vector, pVEGF-Luc. After the transfection, the cells were
cultured for 12 h, followed by incubation in the absence or presence of LY294002 at the
indicated concentrations for 24 h (A) and 36 h (B). The relative luciferase activity was
determined by the ratio of luciferase:β-gal activity and normalized to the control in the cells. C
and D, Cells were co-transfected with pCMV-β-gal plasmid and a VEGF reporter containing a
46 bp functional human VEGF promoter with HIF-1 binding site, pMAP11wt. The cells were
cultured and treated with LY294002 for 24 h (C) and 36 h (D) as described above. E, The cells
were co-transfected with pCMV-β-gal plasmid and the pMAP11mut, which contained three base
pair substitutions at the HIF-1 binding site of pMAP11wt. The cells were treated with
LY294002 as described above for 36 h. F and G, OVCAR-3 (F) and A2780/CP70 (G) cells
were treated with DMSO or LY294002 for 24 h and 36 h. VEGF protein levels were analyzed
by ELISA using 100 μl of media as described in Materials and Methods, and the values were
normalized to the control. * indicates a significant difference from the control (p<0.05).
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Figure 2. HIF-1α reversed LY294002-inhibited VEGF transcriptional activation. A, OVCAR-3
cells were seeded at 0.5x 106 cells/well on a 6-well plate the day before the transfection. The
cells were co-transfected with pCMV-β-gal, pCEP4-HIF-1α, and pVEGF-Luc or pMAP11wt
plasmids. The parental pCEP4 vector was used to adjust the equal amount of plasmid used for
each transfection. The cells were incubated for 12 h after transfection, and then treated with
DMSO alone or 10 μM LY294002 for 24 h. The relative luciferase activity was determined by
the ratio of luciferase:β-gal activity and normalized to the control. B, The cells were cotransfected with pCMV-β-gal, pVEGF-Luc, and pCEP4 vector or HIF-1α dominant negative
construct. The cells were incubated for 12 h after transfection and then treated with DMSO
alone or 10 μM LY294002 for 24 h. The relative luciferase activity was determined as described
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above. * indicates a significant difference from the control (p<0.05). # indicates a significant
difference from the LY294002-treated group (p<0.05).

Figure 3. HIF-1α expression is inhibited by PI3K inhibitor LY294002 in ovarian cancer cells.
A, Four human ovarian cancer cell lines (A2780, A2780/CP70, SKOV-3, and OVCAR-3) were
cultured to confluence in 60 mm dishes in RPMI supplemented with 10% FBS, 5% L-glutamine,
5% penicillin-streptomycin and 0.2% insulin at 37°C in 5% CO2. The cells were treated with
DMSO or 20 μM LY294002 for 6 h. The HIF-1α and HIF-1β protein levels were analyzed by
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immunoblotting using antibodies specific for HIF-1α and HIF-1β. B, The cells were cultured to
90% confluence, then switched to serum-free medium for 24 h. The cells were incubated in the
absence or presence of 10% serum and LY294002 (10 or 20 μM) for 6 h. Aliquots (40 μg) of
total cellular proteins were analyzed by immunoblotting using antibodies specific for HIF-1α
and HIF-1β. C, The serum-starved cells were pretreated with DMSO, 20 μM LY294002, or 100
nM wortmannin for 30 min, followed by the addition of 200 nM insulin or 4 nM IGF-1 as
indicated for 6 h. HIF-1α and HIF-1β proteins were analyzed as described above.
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Figure 4. AKT is essential for VEGF transcriptional activation. A, AKT activation was inhibited
by LY294002 in ovarian cancer cells. A2780, A2780/CP70 and OVCAR-3 cells were cultured
to 90% confluence and switched to serum-free medium for 24 h. The cells were pretreated with
LY294002 for 30 min, followed by treatment with 10% FBS for 1.5 h. The phospho-AKT and
total AKT protein levels were analyzed by immunoblotting. B and C, AKT reversed LY294002inhibited VEGF transcriptional activation. OVCAR-3 cells were seeded at 0.5x 106 cells/well on
a 6-well plate the day before the transfection. The cells were co-transfected with pCMV-β-gal
control, the pVEGF-Luc reporter, and a constitutively active AKT (Myr-AKT) plasmid or the
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vector. The cells were cultured for 12 h after transfection, and then treated with DMSO and 10
μM LY294002 (B) or with DMSO alone (C), for 24 h. The relative luciferase activity was
determined by the ratio of luciferase:β-gal activity and normalized to the control. * indicates a
significant difference from the control (p<0.05). # indicates a significant difference from the
LY294002 treatment (p<0.05).
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Figure 5. Rapamycin inhibited VEGF transcriptional activation and VEGF protein levels in
ovarian cancer cells. A and B, To test the effect of rapamycin on VEGF transcriptional
activation, OVCAR-3 cells were co-transfected with pCMV-β-gal plasmid and pVEGF-Luc (A)
or pMAP11wt plasmid (B). The cells were incubated for 12 h after transfection, followed by the
treatment with DMSO, or rapamycin (5 or 10 ng/ml) for 24 h and 36 h. The relative luciferase
activity was determined by the ratio of luciferase:β-gal activity and normalized to the control. C
and D, To study the VEGF protein levels in the cells, OVCAR-3 (C) and A2780/CP70 (D) cells
were treated for 24 h with rapamycin. The VEGF protein levels in the cultured medium were
analyzed by sandwich ELISA as described in Materials and Methods, and the VEGF protein
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levels were normalized to the control as the relative VEGF protein levels. * indicates a
significant difference from the control (p<0.05).

Figure 6. Expression of p70S6K1 reversed LY294002-inhibited VEGF transcriptional
activation. OVCAR-3 cells were seeded at 0.5x 106 cells/well on a 6-well plate the day before
the transfection. The cells were transfected with pCMV-β-gal, pVEGF-Luc, and p70S6K1 or
vector plasmid. The cells were cultured and treated with DMSO and LY294002 (A) or DMSO
alone (B) for 24 h as described above. The relative luciferase activity was determined in the cells
as described above. *indicates a significant difference from the control (p<0.05). # indicates a
significant difference from the LY294002-treated group (p<0.05).
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Figure 7. Rapamycin inhibited HIF-1α expression in ovarian cancer cells. A, OVCAR-3 and
A2780/CP70 cells were cultured to 90% confluence, and switched to serum-free medium for 24
h. The cells were pretreated with rapamycin at the indicated concentrations for 30 min, and then
incubated with or without 10% FBS for 6 h. HIF-1α and HIF-1β protein levels were analyzed
by immunoblotting as described above. B, A2780/CP70 cells were cultured as described above
and then pretreated with rapamycin as indicated for 30 min, followed by the incubation with or
without 4 nM IGF-1 or 200 nM insulin for 6 h. HIF-1α and HIF-1β were analyzed as described
above.
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Figure 8. LY294002 treatment inhibited HDM2 phosphorylation and protein levels. OVCAR-3
cells were cultured in RPMI media supplemented with 10% fetal bovine serum to 80%
confluence, and then treated with 20 μM LY294002 for different times as indicated. Aliquots
(40 μg) of cellular protein extracts were analyzed using antibodies specific for phospho-HDM2,
total HDM2, and β-actin by immunoblotting.
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Figure 9. HDM2 reversed LY294002-inhibited VEGF transcriptional activation. OVCAR-3
cells were seeded at 0.5x 106 cells/well. A, To test the effect of HDM2 on VEGF transcriptional
activation, the cells were co-transfected with pCMV-β-gal, HDM2, and pVEGF-Luc or
pMAP11wt plasmids as indicated. The cells were cultured overnight, and then treated with
DMSO alone or 10 μM LY294002 for 24 h. The relative luciferase activity was determined as
described above. B, To test whether the HIF-1 binding in the VEGF promoter is essential for
mediating VEGF transcriptional activation, cells were co-transfected with pCMV-β-gal and
pMAP11mut plasmid with the empty vector or pCMV-HDM2. The cells were treated as
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described above, and the relative luciferase activity was determined in the cells. * indicates a
significant difference from the control (p<0.05). # indicates a significant difference from the
LY294002-treated group (p<0.05).

Figure 10. HDM2 transfection increased VEGF protein production in the presence of
LY294002. OVCAR-3 cells were seeded at 0.5x 106 cells/well on a 6-well plate the day before
the transfection. The cells were transfected with 2 μg of empty vector or pCMV-HDM2
plasmid. The cells were cultured for 12 h after transfection, and then treated with DMSO or 10
μM LY294002 for 24 h. The VEGF protein levels in the medium were analyzed by ELISA and
normalized to the control. * indicates a significant difference in VEGF levels from the control.
# indicates a significant difference in VEGF levels from the LY294002-treated group (p<0.05).

- 38 -

Figure 11. HDM2 reverses LY294002-inhibited HIF-1α expression. A2780/CP70 cells were
transfected with either pcDNA3 vector or pcDNA3-HDM2 as described previously. After the
transfection, the cells were selected with G418 for two weeks. Resistant colonies were pooled
and cultured in the presence of low levels of G418 to maintain selection pressure. The cells were
cultured in serum-free medium for 24 h, followed by incubation in the absence or presence of
10% serum and 20 μM LY294002 for 6 h. Aliquots of protein extracts were analyzed using
antibodies specific for HIF-1α and HIF-1β by immunoblotting.
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Abstract
Hypoxia inducible factor-1 (HIF-1) is a basic-helix-loop helix transcription factor composed of
two subunits, HIF-1α and HIF-1β. HIF-1α is a regulatory subunit, which is stabilized in
response to several stimuli including hypoxia, growth factors, and oncogenes. HIF-1α is
overexpressed in the majority of human cancers including ovarian cancer. In this study we
showed that inhibition of HIF-1α by stable expression of small interfering RNA (siRNA) against
HIF-1α (siHIF-1α) decreased ovarian cancer cell motility and invasion. The siHIF-1α
expression dramatically decreased HIF-1α and VEGF expression. When ovarian cancer cells
expressing either scramble siRNA or siHIF-1α were mixed with Matrigel, and injected into the
chicken embryos or nude mice subcutaneously, expression of siHIF-1α greatly decreased tumor
growth and angiogenesis. However, the same ovarian cancer cells without Matrigel were
implanted into nude mouse, which allows the direct contact of cancer cells with the pre-existing
blood vessels, the expression of siHIF-1α increased tumor growth without affecting tumor
angiogenesis. These studies suggest that HIF-1α is required for tumor growth in vivo in a
microenvironment, which requires angiogenesis, but HIF-1α is not required for tumor growth if
the host microenvironment contains sufficient existing vasculatures to support tumor growth.
This study suggests that HIF-1α expression has different effects on tumor growth and
angiogenesis based on the microenvironments.
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Introduction
High expression levels of hypoxia inducible factor-1 (HIF-1) are associated with several
predictors of negative outcomes in human cancer, such as angiogenesis and metastasis. HIF-1 is
a basic helix-loop-helix transcription factor composed of HIF-1α and HIF-1β subunits (13,24).
HIF-1β is constitutively expressed in cells (13), while HIF-1α is upregulated by hypoxia, growth
factors and oncogenes such as Ras and v-Src (2,11,12). HIF-1α is predominantly regulated at the
post-translational level via the prolyl hydroxylation of two proline residues: Pro402 and Pro564
(9,10,15). Under normoxic conditions, prolyl hydroxylases (PHDs) hydroxylate proline residues
in HIF-1α, which allows for the binding of an E3 ubiquitinylation complex given specificity by
the von Hippel Lindau protein (pVHL) (4,10,15). However, under hypoxic conditions HIF-1α is
not hydroxylated, which prevents both the binding of pVHL to HIF-1α and its subsequent
ubiquitinylation.
Previously, we and others have shown that HIF-1α expression is upregulated in a PI3Kdependent manner in several types of cancer (12,22,27). HIF-1α stabilization is associated with
mutations in the tumor suppressor genes VHL and PTEN (4,12,14,29). Also, activation of PI3K
and its downstream target mTOR has been shown to increase HIF-1α expression under normoxic
conditions (8,19). This regulation is especially relevant to ovarian cancer in which PI3K is
frequently mutated, leading to increased activation of PI3K and mTOR signaling pathways and,
consequently, high basal expression of HIF-1α (16,21,22,26).
HIF-1 can upregulate several hypoxia-responsive genes, including VEGF, heme oxygenase 1 and
inducible nitric oxide synthase (20). Expression of HIF-1α is elevated in a large number of
human solid tumors, including prostate, ovarian, lung, breast, and colon cancers (28). Studies
addressing the inhibition of HIF-1α expression in in vivo models of human cancer have produced
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contradictory results. Forced expression of HIF-1α leads to increased tumor growth and
angiogenesis in nude mice (17). But a recent study has shown that HIF-1α-/- MEFs generated
tumors that were larger than those derived from normal MEFs (1). Others have shown that
genetic inhibition of HIF-1α via dominant-negative constructs decreased pancreatic and gastric
tumor growth and angiogenesis (3,23). But, it has not yet been determined that the primary
effect of inhibiting HIF-1α in tumors is due to decrease of angiogenesis In at least one study it
was shown that inhibiting HIF-1α decreases tumor growth but not as a result of inhibiting
angiogenesis (18). These inconsistent results may derive partly from differences in the
experimental conditions, such as the use of a different cell types or the use of a different assay
system. Particularly, because the tumor microenvironment is critical to angiogenesis, the
different tumor microenvironment between these studies could account for many of the variable
findings. To address the function of HIF-1α in ovarian tumor growth and angiogenesis, we used
small interfering RNA (siRNA) to knock down HIF-1α expression in ovarian cancer cells, and
used these cells to generate tumors in either blood vessel poor or blood vessel rich
microenvironments using the same ovarian cancer cells to determine whether the tumor
microenvironments affected the role of HIF-1α in ovarian tumor growth and angiogenesis.

Materials and Methods
Reagents and Cell Culture—The human ovarian cancer cells A2780/CP70, OVCAR-3 and
SKOV-3 were cultured in RPMI 1640 media supplemented with 10% FBS (Intergen, Purchase,
NY), 0.2 units/ml penicillin, and 50 μg/ml streptomycin (Invitrogen, Carlsbad, CA). Cells were
cultured at 37ºC in a 5% CO2 incubator and trypsin (0.25%) was used to detach adherent cells for
subculture.
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Immunoblot Analysis—Cells were washed 3 times in cold PBS, harvested, and lysed in RIPA
buffer containing 1mM sodium vanadate, 0.5 mM dithiothreitol (DTT), 1 mM
phenylmethylsulfonyl fluoride (PMSF), 2 mM leupeptin, 2mM aprotinin, and 2 mM pepstatin on
ice for 20 min. Whole cell lysates were obtained by centrifugation at 13,000 rpm for 15 min at
4ºC. Total cellular protein concentration was assayed using the Bio-Rad® protein assay reagent
(Richmond, CA). Aliquots (40 μg) of protein were loaded onto an SDS/polyacrylamide gel and
resolved via electrophoresis. Proteins were then transferred to a nitrocellulose membrane and
blocked in 5% nonfat dry milk in 1xTBS-T. Proteins were detected via horseradish-peroxidase
conjugated antibodies (NEN, Boston, MA) and visualized through enhanced chemiluminescence
reagent (NEN, Boston, MA).

Luciferase Assay—The human VEGF reporter used was constructed via the insertion of a 2.65
kb KpnI-BssHII fragment of the human VEGF gene promoter into the pGL2-basic vector
(Promega, Madison, WI) (pVEGF-Luc). The β-galactosidase/CMV promoter was used as a
control plasmid for transfection efficiency. To perform the luciferase assay, cells were seeded in
a 12-well plate at a density of 0.3x106 cells per well. After 12 h of culture the cells were washed
twice with warm 1xPBS and transfected with lipofectamine (Sigma) per the manufacturer’s
instructions. Briefly, 0.5 μg were mixed with 2 μl/well Lipofectamine in serum-free Opti-MEM
media (Invitrogen, Carlsbad, CA) and allowed to incubate for 30 min. This solution was then
added to the cells and allowed to incubate at 37ºC for 4.5 h. The Lipofectamine was then
removed and cells were cultured as described previously for 24 h, after which the cells were
collected in luciferase lysis buffer (Promega, Madison, WI) per the manufacturer’s instructions.
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Briefly, 250 μl of luciferase lysis buffer was added to each well and placed at -70ºC until frozen.
Cells and lysis buffer were allowed to thaw and were spun at 13,000 rpm for 1 min at 4ºC. The
supernantant was incubated with luciferase substrate (Promega, Madison, WI), and the results
were measured by a monolight luminometer. β-galactosidase (β-gal) activity was determined as
a control by the hydrolysis of onitrophenyl-b-D-galactopyranoside (ONPG) at 37ºC for 1 h.

Generation of Cancer Cell Lines Stably Expressing siHIF-1α—siRNA specific for HIF-1α was
designed using a siRNA target finder program available at the website of Ambion, Inc. (Austin,
TX). Oligonucleotide DNA sequences encoding HIF-1α siRNA were then inserted into the
pSilencer Neo vector (Ambion, Austin, TX). A commercially available pSilencer Neo vector
containing a siRNA sequence of no known mammalian homology was used as a control
(Ambion, Austin, TX). Control or siHIF-1α constructs were transfected into cancer cells via
Lipofectamine per the manufacturer’s instructions. After 24 h of culture, 500 μg/ml G418 was
added to the media. Over the course of two weeks cells were selected for control or siHIF-1α
expression and the resultant colonies were pooled. No differences in cell morphology or basal
levels of apoptosis were observed following selection of stably-expressing siHIF-1α cells.

Wound Healing and Invasion assays—To determine cell motility the cells were cultured in 6well plates to 80% confluence. Wounds were made in the center of each well using a p200 pipet
tip and wells were washed twice in warm PBS after wounding. Cells were cultured as described
previously for the indicated times then fixed using 3.5% formalin and stained with hematoxylin.
Cell distance was measured and normalized to the control. To determine invasion, 0.5x106 cells
were placed in the upper chamber of an invasion chamber (BD Biosciences, San Jose, CA),
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which is separated from the lower chamber by a membrane covered with Matrigel and containing
8.0 μM pores. Cells in the upper chamber were cultured for the indicated times in RPMI 1640
media containing 1% FBS, while the lower chamber was filled with media containing 10% FBS.
Cells were removed from the upper surface of the membrane insert, and then the insert was fixed
in 3.5% formalin and stained using hematoxylin. Invasion was measured by counting the
number of cells on the lower surface of the membrane.

CAM Tumor Assay—Chicken embryos (CBT Farms) were incubated at 37°C with gentle
rotation. On E8, the embryonic air sac was punctured and moved via vacuum pressure to the
superior surface of the embryo. This area was then exposed, revealing the CAM. To generate
tumors on the CAM 1x107 OVCAR-3 cells were resuspended in RPMI 1640 media and mixed
with an equal volume of Matrigel (BD Biosciences, San Jose, CA) and implanted onto the
exposed CAM. The eggshell was then sealed with transparent tape. Each group contained 8
embryos. On days 6 and 10 of post-implantation, the resultant tumors were photographed,
weighed and either fixed in 10% formalin or frozen for protein analysis.

Nude Mouse Tumor Assay—Nude mice were housed in accordance with WVU’s Animal Care
and Use Committee guidelines. For tumor generation, 1x107 OVCAR-3 cells were resuspended
in RPMI 1640 media and were either injected subcutaneously into the flank of each mouse
directly or mixed with an equal volume of Matrigel. The resultant tumors were measured
periodically and tumor volume was calculated using the formula 0.4 x (L x W2) where W is the
shortest dimension. Tumors were photographed, weighed and either fixed in 10% formalin,
frozen for protein analysis or placed in cold PBS overnight for hemoglobin assay.
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Results

Stable transfection of siHIF-1α inhibited HIF-1α mRNA and protein expression as well as VEGF
transcriptional activation. Previously, we demonstrated that HIF-1α basal levels are elevated in
some ovarian cancer cell lines (22). To determine the significance of this phenomenon, siRNA
specific to HIF-1α was designed, and inserted into a vector containing neomycin resistant gene
(siHIF-1α). We then generated several different ovarian cancer cell lines stably expressing
siHIF-1α or a control siRNA with no known homology to any mammalian target. HIF-1α
mRNA and protein expression levels were inhibited by stable expression of siHIF-1α in
OVCAR-3 cells (Figs. 1A and 1B). To test whether siHIF-1α inhibited VEGF transcriptional
activation, we measured VEGF reporter activity via luciferase assay. The results showed a
dramatic decrease in OVCAR-3 cells stably expressing siHIF-1α (Figs. 1C and 1D). Similar
results were obtained in A2780/CP70 and SKOV-3 cells stably expressing siHIF-1α, which
showed a dramatic reduction in HIF-1α expression and VEGF reporter activity in both cell lines
stably expressing siHIF-1α (Figs. 1E-1H). These results demonstrate that siRNA against HIF-1α
can reduce the expression of HIF-1α and its downstream target, VEGF, in ovarian cancer cells.

siRNA-mediated inhibition of HIF-1α decreased cell migration and invasion. Previously, it has
been shown that HIF-1α may play a role in cell invasion and metastasis. To determine whether
stable expression of siHIF-1α decreased cell migration in ovarian cancer cells, the motility of
OVCAR-3 and SKOV-3 ovarian cancer cells stably expressing siHIF-1α was measured using the
wound healing assay. A wound was made and observed at the time periods indicated. As shown
in Figs. 2, expression of siHIF-1α led to dramatic reductions in the wound healing in both
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OVCAR-3 and SKOV-3 cells at various time periods (Figs. 2A and 2B). Cell proliferation was
not decreased in either cell line by siHIF-1α in the same experiment (data not shown).
Furthermore, stable expression of siHIF-1α dramatically decreased cell invasion in both SKOV-3
and A2780/CP70 cells with 5-fold and 8-fold reduction, respectively (Figs. 2C and 2D). These
data demonstrate that HIF-1α expression plays an important role in both cell migration and
invasion in ovarian cancer cells.

Inhibition of HIF-1α expression by siRNA decreased angiogenesis and tumor growth in the
CAM. To determine the significance of inhibiting HIF-1α via siRNA in an in vivo model of
ovarian cancer, we mixed 1x107 OVCAR-3 cells stably expressing either scramble siRNA or
siHIF-1α with an equal volume of Matrigel, and implanted onto the CAM. These tumors were
then observed and collected in 6 and 10 days post-implantation. Ovarian tumors stably
expressing siHIF-1α exhibited decreased angiogenesis and tumor growth (Figs. 3A-C). HIF-1α
expression was dramatically decreased in siHIF-1α expressing tumors, indicating that the siRNA
inhibited HIF-1α expression, in vivo (Figs. 3D and 3E). PCNA expression was dramatically
decreased in the siHIF-1α tumors, indicating that siHIF-1α decreased cell proliferation in tumors,
probably due to the inhibition of angiogenesis (Figs. 3E). These data suggest that inhibition of
HIF-1α via siRNA decreased both angiogenesis and tumor growth in the CAM tumor model, in
which the nascent tumor does not have direct contact with pre-existing vasculature.

Inhibition of HIF-1α expression by siRNA decreased tumor growth in a nude mouse Matrigel
model. To further study how inhibition of HIF-1α affects ovarian tumor growth and
angiogenesis in another avascular microenvironment, we mixed 1x 107 OVCAR-3 cells with an
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equal volume of Matrigel, and injected subcutaneously into the nude mouse flank. We collected
the tumors 26 days after the implantation. The tumors stably expressing siHIF-1α were
dramatically smaller and weighed less than the control tumors (Figs. 4A and 4B). HIF-1α and
VEGF expression was decreased in siHIF-1α-expressing tumors, demonstrating that siHIF-1α
also has the same effect in vivo, as described above (Figs. 4C). The tumors expressing siHIF-1α
showed reduction in cell proliferation (Figs. 4D). Tumor angiogenesis was also decreased in
siHIF-1α expressing tumors as evidenced by decreased density of blood vessels positively
stained by CD31, and by the reduction of hemoglobin content in the tumors (Figs. 4E and 4F).
Thus, in tumors generated from cells isolated from the host microvasculature, inhibition of HIF1α expression decreased both tumor growth and angiogenesis. This data is consistent with the
results of tumor growth and angiogenesis using the CAM model.

Inhibition of HIF-1α expression increased tumor growth in a nude mouse model in a
subcutaneous microenvironment. There are contradictory results in terms of the roles of HIF-1α
in tumor growth in different model systems. We hypothesized that HIF-1α may not affect
ovarian tumor growth and angiogenesis with a sufficient pre-existing vascular structure. To test
his hypothesis, we injected 1x 107 OVCAR-3 cells in 1x PBS buffer subcutaneously into the
nude mouse flank. Matrigel was not used in this experiment; thus, tumor cells were directly
exposed to the pre-existing blood vessels in the subcutaneum. We monitored tumor growth by
measuring the height and width of tumors when they became visible, and harvested the tumors
26 days after the implantation. In contrary to the results obtained from both the chicken CAM
and the nude mouse experiments above, in which the tumor cells were implanted into the animal
in a Matrigel matrix, tumors induced by siHIF-1α-expressing cells were significantly larger than
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the control tumors (Figs. 5A and 5B). To confirm that the siHIF-1α decreased HIF-1α and
VEGF expression in the tumors in this model, we analyzed HIF-1α and VEGF expression in
tumor sections and tissue lysate, and found that both HIF-1α and VEGF expression was greatly
inhibited in the siHIF-1α-expressing tumors (Figs. 5C and 5D). This result suggests that the
tumor growth is independent of HIF-1α and VEGF expression in this tumor model. To further
study whether siHIF-1α affects cell proliferation and angiogenesis in this model, tumor tissues
were analyzed with antibodies against PCNA, a cell proliferation marker. We found that the
control and siHIF-1α-expressing tumors showed similar PCNA levels, suggesting that they have
similar levels of cell proliferation (Figs. 5C). We also found that there is no significant
difference in angiogenesis with similar hemoglobin content between the control and siHIF-1α
tumors (Figs. 5E). These results suggest that the pre-existing host microvasculature is sufficient
to support tumor growth without the expression of HIF-1α. Taken together, these results showed
that HIF-1α is required for inducing angiogenesis and tumor growth when tumors are generated
in an avascular microenvironment, but that HIF-1α is not required for inducing angiogenesis and
tumor growth when tumors are in the presence of a pre-existing vascular network.

Discussion

HIF-1α is overexpressed in many types of human cancers. It has been associated with
tumor aggressiveness, and high patient mortality rates. In this study we use ovarian cancer cells
stably expressing siRNA specific for HIF-1α. These siRNA-expressing cells exhibited decreased
cell motility and invasion compared to the control cells, suggesting that HIF-1α expression is
critical to ovarian cancer cell migration and invasion. HIF-1α expression is correlated with
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metastasis in several types of human cancer (28). Hypoxia also induces cell motility and
invasion (6,25). Our data provides a possible explanation for these data.
Studies examining the inhibition of HIF-1α in vivo have produced contradictory results.
The effect of HIF-1α on tumor angiogenesis also remains to be defined. One recent study
showed that inhibition of HIF-1α has no effect on tumor angiogenesis (18), while others have
documented that the inhibition of HIF-1α greatly decreased angiogenesis (1,3,23). We
speculated that these contradictory data were due to the use of different cell types and tumor
models. To test this hypothesis, we inhibited HIF-1α expression using a HIF-1α siRNA
construct stably expressed in the same cell line to study its effect in tumor growth and
angiogenesis. HIF-1 siRNA approach has an advantage over HIF-1α dominant-negative
constructs, in that HIF-1 siRNA specifically inhibits HIF-1α expression, while HIF-1 dominantnegative construct may exert other effects by binding to HIF-1β and other partners such as
Mdm2 and p53. Similarly, HIF-1α siRNA approach has an advantage over the inhibition of HIF1β (ARNT) which also binds to HIF-2α and HIF-3α (5,7), thus inhibiting HIF-1β may exert
non-specific effects on other targets.
In this study, we show that inhibition of HIF-1α via siRNA decreased ovarian tumor
growth and angiogenesis in the CAM model (Figs. 3) as well as in a mouse subcutaneous
xenograft model (Figs. 4). Both of these models involved the implantation of the cancer cells
within Matrigel to prevent the direct contact of cancer cells with pre-existing blood vessels.
However, inhibition of HIF-1α via siRNA increased tumor growth in the nude mouse xenograft
model in the absence of Matrigel (Figs. 5). Thus, HIF-1α expression is required in the context of
an avascular microenvironment to recruit a de novo microvasculature that will allow tumor
growth beyond a small size. However, in a microenvironment possessing a vascular network,
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this process is not necessary. It was known that the expression of HIF-1α by tumors may be proapoptotic, leading to upregulation of BNIP 3 and other pro-apoptotic proteins. This could
account for higher tumor growth induced by HIF-1α siRNA-expressing cells than by the control
cells in blood vessel-rich microenvironment (Figs. 5).
The current study showed that HIF-1α has conflicting roles in tumor growth in vivo. Our
data suggest that the effects of HIF-1α in mediating tumor growth and angiogenesis vary based
on the microenvironments. These results have important implication for the utilization of HIF1α inhibition therapy as a cancer treatment. Our results suggest that the efficacy of using a HIF1α inhibitor to treat cancer may be determined by the location and surrounding
microenvironment of the tumor in addition to the tumor types. Primary tumors and metastases to
some locations may be successfully treated with a HIF-1α inhibitor if their microenvironment is
fairly avascular; however, this mode of treatment may increase tumor growth if a tumor is in a
rich pre-existing blood vessel network.
Taken together, this study uses HIF-1α siRNA to specifically inhibit HIF-1α expression
in ovarian cancer cells. We showed the specific roles of HIF-1α in inhibiting cancer cell
migration and invasion without affecting cell proliferation in vitro. In this study, we specifically
inhibited HIF-1α using siRNA, and use the same cell lines expressing HIF-1α siRNA or control
siRNA to study the effects of HIF-1α in tumor growth and angiogenesis. This approach
overcomes the variation of different cell types and potential non-specific effects from other HIF
interaction proteins on the tumor growth and angiogenesis. We demonstrated that the effects of
HIF-1α in tumor growth and angiogenesis vary based on the microenvironments, in which
tumors grow. These data provide a reasonable explanation of previous conflicting results of
HIF-1 in tumor growth and angiogenesis.
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Figure 1. Expression of siRNA against HIF-1α (siHIF-1α) decreased HIF-1α mRNA and protein
expression, and inhibited VEGF transcriptional activation in ovarian cancer cells. A, OVCAR-3
cells were transfected with either pSilencer 2.1-neo vector carrying scramble siRNA (control) or
siHIF-1α. After transfection, the cells were cultured overnight, and then cultured in medium
containing G418. HIF-1α mRNA levels from the cells expressing scramble siRNA control or
siHIF-1α were analyzed by Northern blot using human HIF-1α cDNA probe. The levels of 18S
RNA served as an internal control. B, HIF-1α and HIF-1β protein levels in the cells expressing
scramble siRNA (control) or siHIF-1α were treated as described above and analyzed by
Immunoblottingting. GAPDH served as an internal control. C, OVCAR-3 cells were cotransfected with pCMV-β-gal plasmids and a VEGF reporter containing the human VEGF
promoter reporter. Relative luciferase activity was determined by the ratio of luciferase:β-gal
activity, and normalized to the control. The graph represents mean + SD of relative luciferase
activities from three replicate experiments. * indicates a significant difference when compared
to the control. D, OVCAR-3 cells were co-transfected with siHIF-1α plasmids and the VEGF
reporter as described above (p<0.05). Relative luciferase activity was determined by the ratio of
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siHIF-1α

luciferase:β-gal activity, and normalized to the control. The graph represents mean + SD from
three replicate experiments. * indicates a significant difference when compared to the control
(p<0.05). E, A2780/CP70 cells were transfected with either the pSilencer 2.1-neo vector
carrying scramble siRNA (control) or siHIF-1α. After transfection, the cells were cultured
overnight, and then cultured in medium containing G418 for three weeks to obtain stable cell
lines. HIF-1α protein levels were analyzed by immunoblotting. β-actin served as an internal
control. F, A2780/CP70 cells expressing scramble siRNA or siHIF-1α.were co-transfected with
pCMV-β-gal plasmids and the VEGF promoter reporter. Relative luciferase activity was
determined by the ratio of luciferase:β-gal activity, and normalized to the control. The data
represents mean + SD from three replicate experiments. * indicates a significant difference
when compared to the control (p<0.05). G, SKOV-3 cells were transfected with either the
pSilencer 2.1-neo vector carrying scramble siRNA (control) or siHIF-1α to obtain stable cell
lines as described above. HIF-1α protein levels were analyzed by immunoblotting. β-actin
served as an internal control. H, SKOV-3 cells expressing the control siRNA or siHIF-1α were
co-transfected with pCMV-β-gal plasmids and the VEGF promoter reporter. Relative luciferase
activity was determined by the ratio of luciferase:β-gal activity and normalized to the control.
The data represents mean + SD from three replicate experiments. * indicates a significant
difference when compared to the control (p<0.05).
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Figure 2. Stable expression of siHIF-1α dramatically decreased ovarian cancer cell migration
and invasion. A, OVCAR-3 cells stably expressing a scramble siRNA (control) or siHIF-1α
were cultured in 6-well plates. When the cells reached 80% confluence, a wound was made
using a p200 pipet tip. Representative photos of the wound were taken at 0 h, 12 h, and 36 h.
Relative wound width was measured by quantitative analysis to get the average distance of the
cell migration from three independent experiments with four representative areas per experiment,
and was shown as mean + SD. * indicates a significant difference when compared to the 0 h
control (p<0.05), # indicates a significant difference between control and siHIF-1α at the
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*#

*

24 h 48 h

indicated time point (p<0.05). B, SKOV-3 cells stably expressing a scramble siRNA (control) or
siHIF-1α were cultured in 6-well plates. The wound healing assay was performed as described
above, and representative photos of the wound were analyzed in 24 h and 48 h, and the relative
wound width was measured by quantitative analysis to get the average distance of the cell
migration as above, and was shown as mean + SD. C, For the invasion assay, SKOV-3 cells
expressing the scramble siRNA or siHIF-1α were cultured in medium containing 2% serum and
placed in the upper chamber. RPMI medium supplemented with 10% serum was placed in the
lower chamber which was coated with collagen. The number of cells on the lower membrane
was counted, and shown as mean + SD. * indicates a significant difference when compared to
the control (p<0.05). D, A2780/CP70 cells expressing the scramble siRNA or siHIF-1α were
cultured as described above. The number of cells on the lower membrane was counted and
analyzed. The graph represents mean + SD. * indicates a significant difference when compared
to the controll (p<0. 05).
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Figure 3. Stable expression of siHIF-1α decreased tumor growth and angiogenesis. Chicken
embryos were prepared as described in Materials and Methods. OVCAR-3 cells expressing the
scramble siRNA or siHIF-1α were implanted onto the CAM. On Days 6 and 10 postimplantation, the tumors were harvested, weighed and stored. A, Representative CAM tissue
alone and OVCAR-3-induced tumors at day 6 and 10. B, The number of blood vessel branch
points per high power field was counted for three separate quadrants in four samples per group,
and mean + SD was showed. * indicates a significant difference when compared to the control
(p<0.05). C, Tumor weight was determined by quantitative analysis (mean + SD). * indicates a
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significant difference when compared to the control (p<0.05). D, Representative tumor sections
derived from cells expressing the scramble siRNA or siHIF-1α were stained using specific
antibodies against HIF-1α. E, Total proteins were prepared from the tumor tissues, and analyzed
by immunoblottingting using antibodies against HIF-1α and PCNA. β-actin served as the
control.
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Figure 4. Stable expression of siHIF-1α decreased angiogenesis and tumor growth in a vascularpoor microenvironment. The tumors were generated from OVCAR-3 cells expressing the
scramble siRNA or siHIF-1α as described in Materials and Methods. Tumors were removed and
weighed 10 days after implantation, the tumor tissues were used for hemoglobin content assay,
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or fixed in 10% formalin solution for immunohistology analysis. A, Photographs of
representative tumors expressing the scramble siRNA or siHIF-1α. B, Relative tumor weight
was analyzed from 10 individual tumors. The data indicates the mean ± SD from the replicate
experiments.

* indicates a significant difference when compared to the control (p<0.05). C,

Cells expressing the scramble siRNA or siHIF-1α were subjected to immunostaining using
antibodies against HIF-1α, VEGF, and PCNA. D, Cells expressing the scramble siRNA or
siHIF-1α were analyzed by immunoblotting with antibodies against HIF-1α, β-actin, and PCNA.
E, Tumor sections were stained with antibodies against CD31, and CD31-positive staining cells
were quantified using high power field in three random areas per tumor and from three tumors.
Expression of siHIF-1α decreased CD31 staining in these tumors. F, Relative CD31 staining
was measured by quantitative analysis from three replicate experiments, and data was shown as
mean + SD. * indicates a significant difference when compared to the control (p<0.05). G, The
hemoglobin content from tumors induced by the cells expressing the scramble siRNA or siHIF1α were measured, and normalized to the control. The relative levels of hemoglobin content are
presented as mean + SD from replicate experiments. * indicates a significant difference when
compared to the control (p<0.05).
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Fig. 5. Stable expression of siHIF-1α increased tumor growth in a vascular-rich
microenvironment. The OVCAR-3 cells expressing the scramble siRNA or siHIF-1α were
injected into the subcutaneum of mice as described in Materials and Methods. A, Tumor
volumes were measured when tumors were visible, and the volumes were calculated using the
equation = 0.4 (length x width2). Tumors were removed at the times indicated and weighed,
stored at -70°C, or fixed in formalin solution. The data represents the mean + SD from replicate
experiments. * indicates a significant difference when compared to the control (p<0.05). B,
Relative tumor weight was measured from eight tumors at the end of the experiment. The data
represents the mean ± SD from replicate experiments. * indicates a significant difference when
compared to the control (p<0.05). C, Total proteins were analyzed for assaying HIF-1α, VEGF,
and PCNA expression by immunostaining. D, Tumor sections from the tumors were analyzed by
immunoblotting using antibodies against HIF-1α, PCNA, and β-actin. E, Hemoglobin levels
from the tumors induced by the cells expressing the scramble siRNA or siHIF-1α, were
measured, and normalized to the control. The data represents mean + SD.
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Abstract
HIF-1 is a heterodimeric basic-helix-loop-helix transcription factor composed of two
subunits, HIF-1α and HIF-1β. The regulatory subunit, HIF-1α, is over-expressed in a large
number of tumors and has been correlated with tumor angiogenesis, metastasis and patient
mortality. HIF-1α is upregulated by hypoxia as well as by growth factors and oncogenes and is
over-expressed in ovarian and prostate cancer cells. Previously, it has been shown that tumor
hypoxia contributes to resistance to chemotherapy. In this study we wanted to determine
whether modulation of HIF-1α expression affected response to chemotherapy in ovarian and
prostate cancer cells. Here we show that inhibition of HIF-1α via siRNA (siHIF-1α) decreased
resistance to several commonly used chemotheraputic agents, including cisplatin, taxol and
doxorubicin, in both ovarian and prostate cancer cells in normoxia and hypoxia. This increased
chemosensitivity in cells expressing siHIF-1α was due to increased levels of drug-induced
apoptosis. Furthermore, forced expression of HIF-1α increased resistance to chemotherapy in
these ovarian and prostate cancer cells, due to decreased levels of drug-induced apoptosis. This
indicates a role for the inhibition of HIF-1α in combination with other conventional modes of
chemoetherapy.
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Introduction
Hypoxia inducible factor-1 (HIF-1) is a heterodimeric basic helix-loop-helix transcription
factor composed of two subunits, HIF-1α and HIF-1β. HIF-1β is constitutively expressed in
most cells, while HIF-1α is induced by a variety of different stimuli including hypoxia (31),
growth factors (30) and oncogenes such as Src (20) and Ras (9,26). HIF-1 regulates the
transcription of a number of different genes controlling multiple processes such as glycolytic
metabolism, cell cycle regulation and angiogenesis (30). Over-expression of HIF-1α is found in
most tumors and is correlated with tumor angiogenesis, tumor metastasis and patient mortality
(2-5,37,38).
HIF-1α expression is regulated at the post-transcriptional level via the E3 ubquitin ligase von
Hippel Lindau protein (pVHL). In normoxia, HIF-1α is hydroxylated due to the activity of a
family of prolyl hydroxylases, which allows it to be bound by pVHL and ubquitinylated
(12,18,19,27,27). However, in hypoxia, these prolyl hydroxylases are inactive, and allowing
HIF-1α and HIF-1β to form the active transcription factor HIF-1. Previously we have shown that
HIF-1α expression is upregulated in normoxia in ovarian and prostate cancer cells via
constitutive activation of phosphatidylinositol-3 kinase (PI3K) signaling (21,32).
One of the most difficult problems to overcome in cancer therapy is that of resistance to
conventional chemotherapy. A number of different factors in the tumor contribute to its ability
to resist drug therapy, one of the most interesting and most recently targeted being tumor
hypoxia. Areas of hypoxia are common in most, if not all, solid tumors, due to inadequate and
defective vascularization (7). Tumor hypoxia is associated with chemotherapy resistance and
poor outcome clinically (6,35). Furthermore, it has been shown that hypoxia increases resistance
to many common anti-tumor drugs in cancer cells (15,22,23,25,29,36). Although some
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chemotherapy resistance seen in hypoxic tumors is due to physical factors such as the increased
distance of hypoxic cells from the vasculature and subsequent decreased drug dosage, molecular
alterations also occur in the cell during hypoxia that have been linked to chemoresistance (16).
One of the molecular mechanisms by which hypoxia could induce chemoresistance is via
activation of HIF-1. Several studies have shown that HIF-1 activation by hypoxia leads to
expression of multi-drug resistance gene 1 (MDR 1) in several cell types (13,14), while another
study showed that HIF-1 dependent down- regulation of Bid is necessary for resistance to
etoposide in colon cancer (15). It has been shown that MEF HIF-1 -/- cells are more sensitive to
certain types of chemotherapy (34). However, the exact mechanism by which HIF-1 activation
affects the molecular response to chemotherapy in cancer cells remains unclear.
Because HIF-1α is over-expressed in prostate and ovarian cancer cells in normoxia, and
hypoxia-induced HIF-1α has been linked to chemotherapy resistance, we wanted to determine
whether specific inhibition of HIF-1α by siRNA would affect ovarian and prostate cancer cell
response to chemotherapy. Furthermore, we wanted to determine whether forced expression of
HIF-1α would increase chemotherapy resistance in these cells.

Materials and Methods
Cell culture and reagents – OVCAR-3, SKOV-3 and A2780/CP-70 ovarian cancer and DU-145
and PC-3 prostate cancer cells were cultured in RPMI 1640 (Mediatech, Verndon, VA)
supplemented with 10% fetal bovine serum supplemented (Intergen, Purchase, NY), 0.2 units/ml
penicillin, and 50 μg/ml streptomycin (Invitrogen, Carlsbad, CA). Cells were cultured at 37ºC in
a 5% CO2 incubator and trypsin (0.25%) was used to detach adherent cells for subculture.
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Cisplatin (CDDP) and doxorubicin (Sigma, St. Louis, MO) were dissolved in 1xPBS. Taxol was
purchased in solution (6ng/ml) (PGC scientifics?) and diluted with 1xPBS.

Generation of cell lines—OVCAR-3, SKOV-3, A2780/CP70, PC-3 and DU-145 cells stably
expressing either siRNA specific for HIF-1α (siHIF-1α) or siRNA with no known mammalian
homology (siControl) were generated as described previously (Skinner et al 2005). Similar
selection methods were used to generate cells stably expressing pcDNA3 or HIF-1α CA.
Briefly, the cells were plated in 6-well plates, the next day the cells were transfected with 0.5μg
of either empty pcDNA3 vector or pcDNA3/HIF-1α CA per well using lipofectamine
(Invitrogen, Carlsbad, CA) per the manufacturer’s instructions. After an overnight recovery the
media was supplemented with 600μg/ml G418. The cells were selected for two weeks, and the
resultant colonies were pooled. No gross differences in morphology or cell proliferation or basal
rate apoptosis were observed.

MTT assay—Cells were plated at 50,000 cells/well of a 96-well plate. The following day, the
cells were washed once in 1xPBS then treated with drugs in RPMI 1640 media containing 10%
fetal bovine serum (normal serum) or 1% fetal bovine serum (reduced serum). The cells were
cultured for 48 h in either 21% O2 or 1% O2 as described above. After treatment, the media was
replaced with RPMI 1640 containing 1mg/ml of MTT (2,3-bis-(2-methoxy-4-nitro-5sulfophenyl)-2H-tetrazolium-5-carboxanilide), which was allowed to incubate at 37ºC in a 5%
CO2 incubator for 4 h. 100 μl of MTT lysis buffer (20% SDS, 50% Metforamide) was then
added to each well and allowed to incubate at 37ºC overnight. The following day, absorbance
was read at 570 nm and the means of quadruplicates were calculated. Values were normalized to
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control and shown as mean ± standard deviation. Estimated IC50 values, representing 50%
relative absorbance, are also shown in tables accompanying each figure.

Immunoblot analysis—Cells were washed 3 times in ice cold 1xPBS then collected and lysed in
RIPA supplemented with protease inhibitors (1mM sodium vanadate, 0.5 mM dithiothreitol
(DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 2 mM leupeptin, 2mM aprotinin, and 2
mM pepstatin) on ice for 20 m. The cells were then spun at 13,000 rpm for 10 m. The
supernatant was assayed for protein concentration and aliquots of 40μg were separated on an
SDS-PAGE polyacrylamide gel. Protein was then transferred to a nitrocellulose membrane and
blocked in 5% nonfat dry milk in 1xTBS-T. Proteins were detected using primary antibodies
directed against HIF-1α (BD biosciences, San Jose, CA), caspase-3 (Santa Cruz biotechnology,
Santa Cruz, CA) PARP (Santa Crux biotechnology, Santa Cruz, CA) and β-actin (Sigma, St.
Louis, MO) and HRP-conjugated secondary antibodies (Pierce, Rockford, IL) and visualized
through enhanced chemiluminescence reagent (Pierce, Rockford, IL).

Mitochondrial function —To quantify apoptosis in cells treated with taxol, mitochondrial
function was assayed using MitoTracker Red CMXRos (Invitrogen, Carlsbad, CA). The cells
were treated for 24 h with drug in reduced serum. After treatment, MitoTracker Red CMXRos
dye was added to the cells and allowed to incubate for 30 m. The cells were then trypsinized,
collected and washed twice in 1xPBS. Fluorescence was then measured using flow cytometry
and normalized to untreated control. Values are presented as means ± standard deviation.
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Results
Treatment with common chemotherapeutic drugs inhibits HIF-1α expression in ovarian and
prostate cancer cells. To determine if commonly used chemotherapeutic agents affected HIF-1α
expression in ovarian and prostate cancer cells, we treated OVCAR-3 ovarian cancer cells with
cisplatin (CDDP) for 6 h and found that the treatment decreased HIF-1α expression in both cells
expressing control siRNA (siControl) and cells expressing siRNA specific for HIF-1α (siHIF-1α)
(Fig. 1 A). Similarly, HIF-1α expression was inhibited by CDDP in SKOV-3 cells stably
expressing siControl or siHIF-1α (Fig. 1 B). We observed similar inhibition of HIF-1α in DU145 and PC-3 prostate cancer cell lines after treatment with taxol (Figs. 1 C & D). Furthermore,
the inhibitory effect of both CDDP and taxol on HIF-1α expression was partially reversed by
expression of HIF-1α CA (Figs. 1 E & F).

Inhibition of HIF-1α via siRNA increased sensitivity to common chemotherapeutic agents in
ovarian and prostate cancer cells. Because chemotherapeutic agents decrease HIF-1α
expression, we wanted to determine if specific inhibition of HIF-1α via siRNA affected the
response to treatment with commonly used chemotherapy agents. To do this we performed an
MTT assay using OVCAR-3 stably expressing siControl or siHIF-1α and treated with CDDP and
taxol. Expression of siHIF-1α dramatically increased the sensitivity of these cells to treatment
with both CDDP and taxol (Figs. 2 A-D). In prostate cancer cells we also observed that
expression of siHIF-1α increased the sensitivity to taxol as well as doxorubicin treatment (Fig 2
E-L). This effect was observed in both 10% and 1% serum conditions.
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Expression of siHIF-1α increases apoptosis induced by chemotherapy treatment. Because
siHIF-1α expression increases chemotherapy sensitivity in the MTT assay even under low serum
conditions, which decreases cellular proliferation dramatically, we believed that expression of
siHIF-1α was mainly affecting drug-induced apoptosis. To determine if the observed increased
sensitivity to chemotherapy in cells expressing siHIF-1α was due to induction of apoptosis, we
treated OVCAR-3 cells stably expressing siControl or siHIF-1α with CDDP for 24 h then
measured caspase-3 activation. Expression of siHIF-1α increased the levels of caspase-3 and
PARP cleavage in the presence of cisplatin, indicating that increased levels of caspase-dependent
apoptosis (Fig. 3A). Similar effects were seen in SKOV-3 ovarian cancer cells expressing either
siHIF-1α (Fig. 3B). We also treated DU-145 and PC-3 cells with taxol and assayed
micochondrial function as a measure of apoptosis, as we have previously found that taxol
induced apoptosis in these cells in the absence of caspase-3 activation (unpublished
observations). We found that expression of siHIF-1α renders cells more sensitive to the proapoptotic effects of taxol in both cell lines (Figs. 3 C & D). Thus, the increased sensitivity to
chemotherapy in the cells expressing siHIF-1α was due to induction of apoptosis.
Expression of siHIF-1α does not increase sensitivity to cisplatin in A2780/CP70 cells, but does
increase their sensitivity to taxol. To determine if HIF-1α plays a role in cisplatin resistance
acquired after therapy with this drug, we treated A2780/CP70 cells with cisplatin. These cells
were generated from the surviving colonies of cells cultured in the presence of cisplatin over a
long period of time, thus acquiring cisplatin resistance. Expression of siHIF-1α had no effect on
sensitivity to cisplatin or cisplatin-induced apoptosis in A2780/CP70 cells (Figs. 4A-C).
However, stable expression of siHIF-1α, did increase sensitivity to taxol in these cells in both
normal and reduced serum conditions (Figs. 4D & E). Thus, it would seem that while inhibition
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of HIF-1α does not affect the pathway involved specifically in cisplatin resistance in these cells,
HIF-1α still plays a role in the general resistance to chemotherapy.

Expression of siHIF-1α increased chemosensitivity under hypoxic conditions. Previously, it has
been shown that hypoxia increases resistance to chemotherapeutic agents. To test whether
inhibition of HIF-1α played a role in this process, we treated OVCAR-3 and PC-3 cells stably
expressing siHIF-1α with chemotherapeutic agents under hypoxic conditions in the same manner
as the previous experiments conducted in normoxia. We found that hypoxia increased
chemoresistance in these cells to both cisplatin and taxol compared to the same treatments in
normoxia (Figs. 5 A & B). Furthermore, stable expression of siHIF-1α in OVCAR-3 cells
dramatically increased chemosensitivity in the presence of both cisplatin and taxol under hypoxic
conditions, partially abrogating hypoxia-induced chemoresistance (Figs. 5 A & B). Furthermore,
this effect was due to increased caspase -3 activation and apoptosis in cells expressing siHIF-1α
(Figs. 5 C). Hypoxia increased resistance to taxol treatment when compared to PC-3 cells
treated in normoxia (Fig. 5 D). Similarly, expression of siHIF-1α increased sensitivity to taxol
treatment in PC-3 prostate cancer cells in hypoxia, partially abrogating the protective effect of
hypoxia (Fig. 5 D). This increase in chemosensitivity was due to the induction of apoptosis in
cells expressing siHIF-1α (Fig. 5 E).

Forced expression of constitutively active HIF-1α (HIF-1α CA) decreases sensitivity to
chemotherapy in both normoxic and hypoxic environments. Because we have observed
significant increases in chemosensitivity due to inhibition of HIF-1α in prostate and ovarian
cancer cells, we wanted to determine whether over-expression of HIF-1α under normoxic
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conditions (HIF-1α CA) would affect chemoresistance. We performed experiments similar to
those above, using cells expressing either empty pcDNA3 vector or HIF-1α CA. In OVCAR-3
cells, a significant reduction in chemosensitivity to cisplatin and taxol was observed in both
normal and reduced-serum conditions due to the expression of HIF-1α CA (Figs. 6 A-D).
Expression of HIF-1α CA in PC-3 cells also decreased sensitivity to taxol and doxorubicin in
both normal and reduced-serum conditions (Figs. 6 F-I). Furthermore, the increase in
chemoresistance in cells expressing HIF-1α CA is due to an abrogation of drug-induced
apoptosis, as measured by either activation of caspase-3 signaling in OVCAR-3 cells (Fig. 6 E)
or increased mitochondrial permeability in PC-3 cells (Fig. 6 J). To determine if forced
expression of HIF-1α would also increase chemotherapy resistance under hypoxic conditions, we
performed the same experimenst as described above under hypoxic conditions. Similarly, we
observed that forced expression of HIF-1α CA exerted a chemoprotective effect. Expression of
HIF-1α CA made OVCAR-3 cells more resistant to treatment with either cisplatin or taxol (Figs.
6 K & L). Furthermore, HIF-1α CA expression also decreased chemosensitivity in PC-3 cells
treated with either taxol or doxorubicin (Figs. 6 M & N). This data indicates that forced
expression of HIF-1α increases chemoresistance to a variety of anti-tumor drugs in ovarian and
prostate cancer cells.

Discussion
In this study we showed that HIF-1α expression directly impacted ovarian and prostate
cancer cell response to commonly used chemotherapeutic drugs. Both cisplatin and taxol
decreased HIF-1α expression. Specific inhibition of HIF-1α increased chemosensitivity in both
normoxia and hypoxia, while forced expression of stable HIF-1α had the reverse effect.
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Furthermore, the effect of HIF-1α in increasing chemotherapy resistance was due to decreased
drug-induced apoptosis.
The cancer cell lines used in this study were either p53 null or express mutant p53.
Therefore, although HIF-1α has been shown previously to interact with p53 and affect its
functioning (1,10,17), it is unlikely that this is the mechanism by which HIF-1α is exerting its
effects on drug-induced apoptosis. Hypoxia regulates a number of targets that are thought to be
involved in resistance to chemotherapy, such as MDR1 and Bid, via HIF-1α expression (13-15).
These factors could be working in combination to explain the dramatic increase in
chemosensitivity seen with inhibition of HIF-1α epression.
This study used several cell lines that exhibit variety of resistance to conventional
chemotherapy. All of the ovarian cancer cell lines used exhibit some resistance to cisplatin,
which was overcome by inhibition of HIF-1α expressoion in all cell lines, except A2780/CP70.
Interestingly, cisplatin resistant A2780/CP70 cells, which were generated from cisplatin resistant
colonies in culture, was unaffected by inhibition of HIF-1α. Previous data has indicated that
A2780/CP70 cells are resistant to cisplatin via alterations in the DNA damage repair pathway
(28). In these cells HIF-1α expression may not be affecting this pathway. Alternatively, because
it has been shown that HIF-1α can affect at least one DNA repair enzyme (24), targets of HIF-1α
in this pathway may be insensitive to regulation in A2780-CP70 cells contributing to cisplatin
resistance.
Currently, inhibitors of HIF-1α are being examined as possible anti-tumor and antiangiogenic agents. HIF-1α inhibition as cancer therapy is promising, as HIF-1α is barely
expressed in normal tissues, but is over-expressed in many tumors and has been linked to tumor
angiogenesis, metastasis and patient mortality (2-5,38). However, the results of HIF-1α
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inhibition in tumor xenograft models have thus far been inconclusive. In several studies,
inhibition of HIF-1α decreased tumor growth (11,33), however other studies indicate that
inhibition of HIF-1α can lead to increased tumor growth (8) (Skinner et al 2005). The results of
this study seem to indicate that inhibition of HIF-1α might be more efficacious in combination
with conventional chemotherapy, than as a stand alone therapy. This would be particularly true
in tumors that are resistant to commonly used chemotherapy drugs, like cisplatin and taxol.
Inhibition of HIF-1α expression would sensitize the tumor to these drugs, allowing for lower
doses which would decrease toxicity and side effects.
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Figure 1. Treatment with common chemotherapeutic drugs decreases HIF-1α expression.
A, OVCAR-3 cells stably expressing either control siRNA (siControl) or siRNA specific for
HIF-1α (siHIF-1α) were treated with CDDP at the indicated doses for 6 h. Levels of HIF-1α and
β-actin expression were analyzed via immunoblotting. B, SKOV-3 cells stably expressing either
control siControl or siHIF-1α were treated with CDDP at the indicated doses for 6 h. Levels of
HIF-1α and β-actin expression were analyzed via immunoblotting. C, DU-145 prostate cancer
cells stably expressing either siControl or siHIF-1α were treated with taxol at the indicated doses
for 6 h. Levels of HIF-1α and β-actin expression were analyzed via immunoblotting. D, PC-3
prostate cancer cells expressing siControl or siHIF-1α.were were treated with taxol at the
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indicated doses for 6 h. Levels of HIF-1α and β-actin expression were analyzed via
immunoblotting. E, OVCAR-3 cells stably expressing either pcDNA3 or HIF-1α CA were
treated with CDDP at the indicated doses for 6 h. Levels of HIF-1α and β-actin expression were
analyzed via immunoblotting. F, PC-3 prostate cancer cells expressing either pcDNA3 or HIF1α CA were treated with taxol at the indicated doses for 6 h. Levels of HIF-1α and β-actin
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Figure 2. Stable expression of siHIF-1α increased sensitivity to common chemotherapeutic
agents. All cells were plated at 50,000 cells/well in a 96-well plate. The following day the cells
were treated with the indicated chemotherapeutic drugs in medium containing either 10% 10% or
1% serum. After 48 h, MTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5carboxanilide) was added to the media, and allowed to incubate for 4 h. The cells were then
lysed and absorbance was read at 570nm. *―indicates significant difference between siControl
and siHIF-1α (p<0.05) A and B, OVCAR-3 cells stably expressing siControl or siHIF-1α were
treated with the indicated doses of cisplatin (CDDP) containing either 10% (A) or 1% (B) serum.
C and D, OVCAR-3 cells stably expressing siControl or siHIF-1α were treated with the
indicated doses of taxol containing either 10% 10% (C) or 1% (D) serum. E and F, DU-145
cells stably expressing siControl or siHIF-1α were treated with the indicated doses of taxol
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containing either 10% (E) or 1% (F) serum. G and H, PC-3 cells stably expressing siControl or
siHIF-1α were treated with the indicated doses of taxol containing either 10% (G) or 1% (H)
serum. I and J, DU-145 cells stably expressing siControl or siHIF-1α were treated with the
indicated doses of doxorubicin containing either 10% (I) or 1% (J) serum. K and L, PC-3 cells
stably expressing siControl or siHIF-1α were treated with the indicated doses of doxorubicin
containing either 10% (K) or 1% (L) serum.
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Figure 3. Stable expression of siHIF-1α increases apoptosis in ovarian and prostate cancer cells
treated with common chemotherapeutic drugs. A, OVCAR-3 cells stably expressing siControl or
siHIF-1α were treated with the indicated doses of cisplatin (CDDP) in serum free medium. After
24 h, the cells were collected and levels of caspase 3 and PARP cleavage were assayed via
immunoblotting. B, SKOV-3 cells stably expressing siControl or siHIF-1α were treated with the
indicated doses of cisplatin (CDDP) in serum free medium. After 24 h, the cells were collected
and levels of caspase 3 and PARP cleavage were assayed via immunoblotting. C, DU-145 cells
stably expressing siControl or siHIF-1α were treated with the indicated doses of taxol in serum
free medium. After 24h Mito- Tracker Deep Red dye was added to the medium, and allowed to
incubate for 30 min. The cells were then fixed with ethanol and florescence was measured via
flow cytometry. Fluorescence was proportional to cell viability as measured by mitochondrial
functioning and was normalized to that of control. *―indicates significant difference between
siControl and siHIF-1α (p<0.05). D, PC-3 cells stably expressing siControl or siHIF-1α were
treated with the indicated doses of taxol in serum free medium. After 24h mitochondrial dye was
added to the media and allowed to incubate for 30 min. The cells were then processed and
analyzed as above. Fluorescence was proportional to cell viability as measured by mitochondrial
functioning and was normalized to that of control. *―indicates significant difference between
siControl and siHIF-1α (p<0.05).
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expressing siControl or siHIF-1α were treated with the indicated doses of cisplatin (CDDP)
containing either 10% (A) or 1% (B) serum. C, A2780/CP70 cells stably expressing either
siControl or siHIF-1α were treated with the indicated doses of CDDP for 24h. The cells were
collected and levels of caspase 3 and PARP cleavage were assayed via immunoblotting. D and
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Figure 5. Stable expression of siHIF-1α increased chemosensitivity in hypoxia due to the
induction of apoptosis. For MTT assays, cells were plated at 50,000 cells/well in a 96-well plate.
The following day the cells were treated with the indicated chemotherapeutic drugs. The cells
were then cultured in a 1% oxygen environment for 48 h. Afterward MTT (2,3-bis-(2-methoxy4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) was added to the medium and allowed to
incubate for 4 h. The cells were then lysed and absorbance was read at 570nm. *―indicates
significant difference between siControl and siHIF-1α (p<0.05). A, OVCAR-3 cells stably
expressing siControl or siHIF-1α were treated with the indicated doses of CDDP (cisplatin) then
cultured in hypoxia for 48h. B, OVCAR-3 cells stably expressing siControl or siHIF-1α were
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treated with the indicated doses of taxol then cultured in hypoxia for 48h. C, OVCAR-3 cells
were treated with the indicated doses of CDDP, then cultured in hypoxia for 24 h. The cells
were then collected and levels of caspase 3 and PARP cleavage were assayed via
immunoblotting. D, PC-3 cells stably expressing siControl or siHIF-1α were treated with the
indicated doses of taxol, and then cultured in hypoxia for 48 h. E, PC-3 cells were treated with
the indicated doses of taxol, and then cultured in hypoxia for 24 h. Mito Tracker dye was then
added to the media, and allowed to incubate for 30 min. The cells were then fixed with ethanol
and florescence was analyzed via flow cytometry. Florescence was proportional to cell viability
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Figure 6. Over-expression of HIF-1α partially reverses the effect of chemotherapy on cancer
cells. MTT assays were performed as described previously. *―indicates significant difference
between siControl and siHIF-1α (p<0.05). A and B, OVCAR-3 cells stably expressing either
pcDNA3 or HIF-1α CA were treated with CDDP at the indicated doses for 48 h containing either
10% (A) and 1% (B) serum containing media. C and D, OVCAR-3 cells stably expressing either
pcDNA3 of HIF-1α CA were treated with taxol at the indicated doses for 48 h containing either
10% (C) and 1% (D) serum containing media. E, OVCAR-3 cells stably expressing either
pcDNA3 of HIF-1α CA were treated with CDDP at the indicated doses. Levels of caspase-3 and
PARP cleavage were visualized via immunoblotting. F and G, PC-3 cells stably expressing
either pcDNA3 or HIF-1α CA were treated with taxol at the indicated doses for 48 h containing
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either 10% (F) and 1% (G) serum containing media. H and I, PC-3 cells stably expressing either
pcDNA3 or HIF-1α CA were treated with doxorubicin at the indicated doses for 48 h containing
either 10% (H) and 1% (I) serum containing media. J, PC-3 cells stably expressing either
pcDNA3 or HIF-1α CA were treated with taxol for 24 h. Mito Tracker dye was then added to
the media and allowed to incubate for 30 min. The cells were then ethanol fixed and florescence
was analyzed via flow cytometry. Florescence was proportional to cell viability and normalized
to control. K and L, OVCAR-3 cells stably expressing either pcDNA3 of HIF-1α CA were
cultured in hypoxia and treated with either CDDP (K) or taxol (L) at the indicated doses for 48 h.
M and N, PC-3 cells stably expressing either pcDNA3 of HIF-1α CA were cultured in hypoxia
and treated with either taxol (K) or doxorubicin (L) at the indicated doses for 48 h.
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ABSTRACT
Hypoxia inducible factor-1 (HIF-1) is a heterodimeric basic-helix loop helix transcription
factor composed of two subunits, HIF-1α and HIF-1β. HIF-1α, the regulatory subunit, is overexpressed in many human cancers and plays an important role in angiogenesis and
tumorigenesis. Cyclooxygenase-2

(COX-2), an enzyme that converts arachadonic acid to

prostanoids such as PGE2, is also activated in many types of cancer and is involved in
angiogenesis. Previously it has been shown that HIF-1α and COX-2 expression are correlated in
tumors and that both are regulated by hypoxia. In this study we show that HIF-1α expression
regulates basal and hypoxia-induced PGE2 production and COX-2 expression in cancer cells.
We also found that HIF-1α regulates COX-2 expression at the transcriptional level via binding to
an HRE located within the COX-2 promoter. Furthermore, we show that HIF-1-dependent
COX-2 expression is regulated by phosphatidylinositol-3 kinase (PI3K) signaling, while PMA
stimulates COX-2 expression in a HIF-1-independent manner through JNK and AP-1. These
data indicate the existence of a possible pro-angiogenic positive feedback loop between HIF-1α,
COX-2 and PGE2 activated by hypoxia in human cancer.
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INTRODUCTION
Hypoxia is common in a variety of human tumors and has been shown to induce the production
of several pro-angiogenic factors such as VEGF via the induction of hypoxia inducible factor-1
(HIF-1) (46). HIF-1 is a basic helix-loop-helix transcription factor composed of two subunits,
HIF-1α and HIF-1β. While HIF-1β is constitutively expressed in cells, HIF-1α expression can
be upregulated by hypoxia, as well as other stimuli including growth factors and oncogenes (44).
HIF-1α protein expression is primarily regulated at the post-transcriptional level via several
prolyl hydroxylase enzymes (PHD 1-4). Under normoxic conditions, PHDs hydroxylate highly
conserved proline residues (Pro402 and Pro564) within a region of HIF-1α dubbed the oxygen
dependent degradation domain (ODD) (19,20,38). This hydroxylation allows binding to HIF-1α
by von Hippel Lindau protein (pVHL), leading to the ubquitinylation and subsequent
degredation of HIF-1α by the proteosome (5,20,38). In the case of hypoxia, PHDs can not
hydroxylate HIF-1α, which prevents its degradation. A variety of growth factors such as IGF-1
and EGF have also been shown to stimulate HIF-1α expression via increased levels of its protein
translation (1,12,52), however the exact mechanism by which these and other growth factors
regulate HIF-1α remains unclear.
Previously, we and others have shown that one of the primary regulators of HIF-1α
expression in response to growth factors is the phosphatidylinositol-3 kinase (PI3K) signaling
pathway (13,18,21,36,47,48,52,58). Growth factor stimulation of HIF-1α expression is
abrogated by inhibition of PI3K (21,47,48,52). Conversely, constitutive activation of PI3K,
observed in several types of cancer including cancer of the ovary and prostate, leads to increased
basal expression of HIF-1α (21,47,57,58). Furthermore, several groups have found that PI3K
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signaling is linked to the stabilization of HIF-1α in hypoxia (18,36), however others have found
contrary results (14,33,34).
Another potent stimuli for angiogenesis in the tumor is the cyclooxygenase 2 (COX-2).
COX-2 is an inducible, dual function enzyme that regulates the conversion of arachadonic acid
precursors in the cell membrane to prostaglandins. Several products of COX-2, such as
prostaglandin E2 (PGE2), thromboxane and prostacyclin, have been shown to promote
angiogenesis (15). Conversely, NSAIDs as well as selective inhibitors of COX-2 inhibit
endothelial cell tube formation (32-34) and angiogenesis in vivo (42). COX-2 expression is
upregulated in a wide variety of cancers including colon, prostate and ovarian cancer.
Furthermore, several specific COX-2 inhibitors are being investigated clinically as possible antitumor agents (15).
COX-2 and HIF-1α expression are regulated by similar stimuli and control similar
processes within the cell. Both are upregulated by hypoxia (14,45) as well as by chemical
mimics of hypoxia, such as CoCl2 and desferroxamine (22,31,51,56). COX-2 and HIF-1α are
induce the production of VEGF and are potent stimulators of angiogenesis (15,46). Expression of
either COX-2 or HIF-1α enhances cell migration (6,28,53) and both are correlated with tumor
invasion and metastasis (26,29,37,59). Previously it has been thought that COX-2 can regulate
HIF-1α expression in a linear fashion. NSAIDs decrease HIF-1α expression, although this effect
has been found to be at least partially COX-2 independent (2,23,39). Furthermore, overexpression of COX-2 or treatment with PGE2 leads to elevated VEGF levels via increased
expression of HIF-1α (17,30). However, the COX-2 promoter has been shown to contain several
hypoxia response elements (2), one of which we predicted to be functional in vivo using
computer software. Because of this, as well as the previously observed correlation between HIF-
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1α and COX-2, we wanted to determine if HIF-1α could regulate COX-2 expression in human
cancer. Furthermore, because of our predicted functional HRE within the COX-2 promoter
(HRE (-576/-584)), we wanted to determine if HIF-1 acted through this HRE to regulate COX-2
transcription.

MATERIALS AND METHODS
Reagents and Cell Culture—OVCAR-3 and A2780 ovarian cancer cells and PC-3 prostate
cancer cells were cultured in RPMI 1640 media supplemented with 10% FBS (Intergen,
Purchase, NY), 0.2 units/ml penicillin, and 50 μg/ml streptomycin (Invitrogen, Carlsbad, CA).
Cells were cultured at 37ºC in a 5% CO2 incubator and trypsin (0.25%) was used to detach
adherent cells for subculture. LY294002 (Calbiochem, San Diego, CA), SP600125
(Calbiochem, San Diego, CA), and SB202190 (Calbiochem, San Diego, CA) were dissolved in
DMSO. Pyrrolidinedithiocarbamate (PDTC) (Sigma, St. Louis, MI) was dissolved in 1xPBS.
For culture in hypoxia, cells were incubated in a hypoxic chamber (Billups-Rothenberg, Del
Mar, CA) with an atmosphere composed of 1% oxygen, 5% CO2, and 94% N2 (Airgas, Radnor,
PA)

Generation of cancer cell lines stably expressing constitutively active HIF-1α and siHIF-1α—
OVCAR-3, A2780 and PC-3 cells stably expressing siHIF-1α were generated as described
previously (Skinner et al 2005). Plasmid DNA encoding HIF-1α with a mutation at Pro564
(ProÆAla) rendering HIF-1α constitutively active (HIF-1α CA) in pcDNA3 vector was a
generous gift from Dr. Frank Lee, UPMC, Pittsburgh, PA.. OVCAR-3, A2780 and PC-3 cells
were transfected with either pcDNA3 or pcDNA3/HIF-1α CA using Lipofectamine (Invirtogen,
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Carlsbad, CA) according to the manufacturer’s instructions. After 24 h of culture, 600 μg/ml
G418 was added to the media and the cells were cultured normally. Surviving colonies after two
weeks were pooled and cultured as described previously. No differences in cell morphology or
basal levels of apoptosis were observed following selection of cells stably expressing pcDNA3
or pcDNA3/HIF-1α CA.

RNA isolation and Real Time RT-PCR—Total mRNA was collected and isolated using Trizol
reagent (Invitrogen, Carlsbad, CA) after treatment according to the manufacturer’s instructions.
2μg of mRNA was used to generate the first strand cDNA using AMV reverse transcriptase
(Promega, Madison, WI). The random oligo d(T) primers were annealed to the template at 42°C
for 5 min. The reaction mixture (20μl) was then incubated at 72°C for 1 hour to allow firststrand synthesis and spun for 1 min at max speed. 5μl of the resultant mixture was then used to
perform Real-time PCR using SYBR-Green master mix and primers for COX-2 and GAPDH
(MJ Research, Waltham, MA). The comparative copy number of each gene in each sample was
calculated using the method of Pfaffl (2001). Samples were also run out on agarose gels for
comparison. COX-2 primers: 5’-TCAGCCATACAGCAAATCCTT-3’ and 5’CTGCACTGTGTTAGTGG-3’. GAPDH primers: 5’-CACCCATGGCAAATTCCATGGCA3’ and 5’-TCTAGACGGCAGGTCAGGTCCACC-3’

Site-directed mutagenesis -- The human full length COX-2 reporter used was a generous gift of
Dr. Jian Li (Harvard Medical School). To generate the HRE mutant COX-2 reporter, we
performed site-directed mutagenesis on the wild type COX-2 reporter according to the
manufacturer’s instructions (Invitrogen, Carlsbad, CA). Briefly, we generated primers specific
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for the HRE (-576/-584) present in the COX-2 promoter containing a three base mutation
(GACÆAAA) which has previously been shown to abrogate HIF-1 binding (11). This primer
was then used to perform PCR on the wild type COX-2 reporter. After PCR replication, the
methylated wild type COX-2 promoter was degraded using Dpn I. The resultant COX-2 mutant
reporter was then electroporated into competent DH5α cells and purified using a Qiagen Midi
prep kit (Qiagen, Valencia, CA).

Luciferase assay—To perform the luciferase assay cells were seeded in a 12-well plate at a
density of 0.3x106 cells per well. After 12 h of culture the cells were washed twice with warm
1xPBS and transfected with lipofectamine (Sigma, St. Louis, MO) per the manufacturer’s
instructions. Briefly, 0.5 μg of the wild type or mutant COX-2 reporter were mixed with 2
μl/well Lipofectamine in serum-free Opti-MEM media (Invitrogen, Carlsbad, CA) and allowed
to incubate for 30 min. The β-galactosidase/CMV promoter was used as a control plasmid for
transfection efficiency. This solution was then added to the cells and allowed to incubate at 37ºC
for 4.5 h. The Lipofectamine was then removed and cells were cultured as described previously
for 24 h, after which the cells treated as described in the Results. After treatment, the cells were
collected in luciferase lysis buffer (Promega, Madison, WI) per the manufacturer’s instructions.
Briefly, 250 μl of luciferase lysis buffer was added to each well and placed at -70ºC until frozen.
Cells and lysis buffer were allowed to thaw and were spun at 13,000 rpm for 1 min at 4ºC. The
supernantant was incubated with luciferase substrate (Promega, Madison, WI), and the results
were measured by a monolight luminometer. β-galactosidase (β-gal) activity was determined as
a control by the hydrolysis of onitrophenyl-b-D-galactopyranoside (ONPG) at 37ºC for 1 h.
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Immunoblot analysis—Cells were washed 3 times in cold PBS, harvested, and lysed in RIPA
buffer containing 1mM sodium vanadate, 0.5 mM dithiothreitol (DTT), 1 mM
phenylmethylsulfonyl fluoride (PMSF), 2 mM leupeptin, 2mM aprotinin, and 2 mM pepstatin on
ice for 20 min. Whole cell lysates were obtained by centrifugation at 13,000 rpm for 15 min at
4ºC. Total cellular protein concentration was assayed using the Bio-Rad® protein assay reagent
(Bio-Rad, Richmond, CA). Aliquots (40 μg) of protein were loaded onto an
SDS/polyacrylamide gel and resolved via electrophoresis. Proteins were then transferred to a
nitrocellulose membrane and blocked in 5% nonfat dry milk in 1xTBS-T. Proteins were detected
via horseradish-peroxidase conjugated antibodies (NEN, Boston, MA), and visualized through
enhanced chemiluminescence reagent (NEN, Boston, MA).

PGE2 ELISA—Cells were plated at 0.1x106 cells/well of a 24-well plate and were allowed to
recover overnight. The following day, the cells were fed with fresh media and then cultured in
normoxia or hypoxia (1%O2) for 24h. The conditioned media was then collected and cleared of
cellular debris by centrifugation at 2,000 rpm for 2 min. PGE2 concentration was then
determined using an ELISA kit per the manufacturer’s instructions (R & D Systems,
Minneapolis, MN).

Chromatin Immunoprecipitation Assay—A2780 ovarian cancer cells were cultured in normoxia
or hypoxia for 8 h. Formaldehyde (1%) was then added to the cells and allowed to incubate at
room temperature for 10 m to cross-link the DNA. Cells were then washed twice in ice cold
PBS and collected in PBS supplemented with protease inhibitors (Leupeptin 2mg/ml, Aprotinin
2 mg/ml, PMSF 0.2 M), spun and lysed in Sonication buffer (1% Triton X-100, 0.1%
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Deoxycholate, 50 mM Tris-Cl pH 8.0, 150 mM naCL, 5 mM EDTA) at 4º C for 10 m. Cell
lysates were sonicated to yield DNA fragments ranging in size from 200-900bp and centrifuged
for 15 m at 4º C. Samples were diluted and pre-cleared with protein A/G Sepharose (40μl) for 1
h at 4º C. Eluates were then incubated with HIF-1α antibody at 4º C overnight. The next day,
40μl of protein A/G agarose was then added and the mixture was allowed to incubate for 2 h.
Sepharose beads were then pelleted and washed sequentially for 10 m at 4º C in TSE I (0.1%
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-Cl pH 8.1, 150 mM NaCL), TSE II (0.1%
SDS, 1% Triton X-100, 2 mM EDTA, 20mM Tris-Cl pH 8.1, 500 mM NaCl) and Buffer III
(0.25 M LiCl, 1% Nonidet P-40, 1% deoxycholate, 1 mM EDTA, 10mM Tris pH 8.1). Beads
were washed another three times in Tris-EDTA, pH 8.0, then the DNA-protein complexes were
eluted in 500 μl of elution buffer. Chemical cross-linking was reversed by incubating the
samples at 65º C for 4 h. DNA fragments were extracted with phenol/chloroform/isoamyl
alcohol and purified using ethanol precipitation. Real-time PCR was performed using the
following primer pairs: VEGF primer pair flanking the HRE 5'GTAGGTTTGAATCATCACGCAGG-3' and 5'-GCACCAAGTTTGTGGAGCTGA-3'; COX-2
primer pair flanking the HRE 5’-TATACAGCCTATTAAGCGTCGTCA-3’ and 5’CGTGTCTGGTCTGTACGTCTTTAG-3’.

Data analysis – Data are expressed as means ± standard error. One-way analysis of variance
(ANOVA) with post-hoc Tukey’s protected t-test was used to determine statistical significance
between and within multiple groups. p<0.05 was considered statistically significant.
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RESULTS

HIF-1α expression regulated basal and hypoxia-induced COX-2 expression. Both HIF-1α and
COX-2 expression are associated with tumor angiogenesis and are over-expressed in cancer.
Several stimuli, such as desferroxamine, CoCl2 and hypoxia stimulate both HIF-1α and COX-2
expression. In light of these data, we wanted to determine if HIF-1α regulated COX-2
expression in cancer. We generated A2780 ovarian cancer and PC-3 prostate cancer cell lines
that stably expressed either siRNA specific for HIF-1α (siHIF-1α; described previously in
Skinner et al 2005) or siRNA with no known mammalian homology (siControl). We also
generated A2780 and PC-3 cells that stably expressed a construct encoding HIF-1α that was
stabilized in normoxic conditions by a mutation in the ODD domain (Pro564ÆAla564) (HIF-1α
CA) or the empty vector (pcDNA3). We then examined COX-2 protein expression and PGE2
production in these cells. Similar to previous results, A2780 and PC-3 cells exhibited detectable
basal levels of COX-2 under normal culture conditions, and COX-2 protein was increased by
hypoxia in both cell lines (Figs. 1A & B). Hypoxia also increased PGE2 levels in the conditioned
media (Figs. 1C & D). Interestingly, in both cell lines, stable expression of HIF-1α CA led to
induction of COX-2 protein, as well as production of PGE2, at levels similar to those seen during
hypoxia in the control cells (Figs. 1 A, C, E & G). Furthermore, in cells expressing HIF-1α CA,
which is greatly stabilized in normoxia, hypoxia led to no increase in either COX-2 protein or
PGE2 (Figs. 1 A, C, E & G). Conversely, inhibition of HIF-1α expression completely abrogated
basal expression of COX-2 as well as basal production of PGE2 (Figs. 1 B, D, F & H).
Expression of siHIF-1α also abrogated the stimulatory effect of hypoxia on COX-2 protein
expression and PGE2 production in both cell lines (Figs. 1 B, D, F & H). To determine if the
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observed effect of HIF-1α expression on COX-2 was due to regulation of COX-2 mRNA
expression, we performed similar experiments as those described above and measured COX-2
mRNA. Again, expression of HIF-1α CA increased COX-2 mRNA expression to levels
normally observed after hypoxic stimulation (Figs. 1 I-L). Furthermore, hypoxia could not
further increase COX-2 mRNA expression in cells expressing HIF-1α CA (Figs. 1 I-L).
Conversely, expression of siHIF-1α dramatically decreased COX-2 mRNA expression and
completely abrogated the effects of hypoxia on COX-2 expression (Figs. 1 I-L). These data
indicate that indeed HIF-1α regulates basal and hypoxia- induced PGE2 production and COX-2
protein and mRNA expression.

PMA-induced COX-2 expression was not regulated through HIF-1α expression. We performed
experiments similar to those above, but used phorbol ester (PMA) to stimulate COX-2
expression. PMA stimulated COX-2 in a dose-dependent and time-dependent manner in both
control and HIF-1α CA expressing cells in both cell lines (Figs. 2 A-C). Expression of siHIF-1α
decreased COX-2 protein expression below the level of detection of immunoblotting (Figs. 2 DF); however inhibition of HIF-1α did not abrogate the stimulatory effect of PMA on COX-2
mRNA expression (Fig. 2 G). The ration between unstimulated and PMA-stimulated groups in
both the pcDNA3 and HIF-1α expressing cells was similar. This indicates that the higher levels
of COX-2 protein in cells stably expressing HIF-1α CA treated with PMA, compared to control
treated with PMA is largely due to the elevated basal levels of COX-2 protein in cells stable
expressing HIF-1α CA. Furthermore, PMA stimulated COX-2 mRNA expression even in cells
that expressed HIF-1α CA, which was not the case for hypoxia-induced COX-2 expression
(Fig. 2G). When we examined the pathways signaling from PMA to COX-2, we found that
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inhibition of JNK, but not PI3K or NF-κB, abrogated the effect of PMA on COX-2 protein
expression in both control and HIF-1α CA-expressing cells, indicating that the primary
transcriptional mediator of PMA-induced COX-2 expression in these cells may be AP-1 and not
HIF-1α or NF-κB (Fig. 2 H).

HIF-1 regulates COX-2 expression at the transcriptional level by binding to a hypoxia
responsive element (HRE) in the COX-2 promoter. Because COX-2 can be regulated at multiple
levels (7,40), we wanted to determine the mechanism by which HIF-1α regulates COX-2
expression. To examine the effect of HIF-1α on COX-2 transcriptional activation, we performed
a series of experiments using the full-length COX-2 promoter coupled to firefly luciferase.
Transfection with either wild type HIF-1α (HIF-1α wt) or HIF-1α CA increased COX-2
transcription in a concentration-dependent manner (Figs. 3 A & B) in OVCAR-3 ovarian cancer
cells. Expression of HIF-1α wt also increased COX-2 transcriptional activity in a concentrationdependent manner in A2780 (Fig. 3 C) and PC-3 cells (Fig. 3 D). Conversely, expression of
either HIF-1α dominant negative (HIF-1α DN) or siHIF-1α led to a concentration-dependent
decrease in COX-2 transcription in OVCAR-3 (Figs. 3 E & F), A2780 (Figs. 3 G & H) and PC-3
(Figs. 3 I & J) cells. Previously it has been shown that the COX-2 promoter has several hypoxia
responsive elements. Although HREs are present in the promoters of many genes, not all are
functional. We predicted that HRE (-576/-584) in the COX-2 promoter would be functional. To
test this hypothesis, we generated a COX-2 reporter construct containing the COX-2 promoter
with a mutation in the HRE (-576/-584) (GACÆAAA) coupled to luciferase (COX-2
MUT/LUC). This mutation has been shown previously to completely abrogate HIF-1 DNA
binding and transcriptional activity (11). We then co-transfected this COX-2 mutant reporter
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with either HIF-1α DN or HIF-1α wt to determine if HIF-1 was indeed binding the HRE (-576/584) to regulate COX-2 expression. Inhibition of HIF-1α had no effect on COX-2 MUT
transcriptional activity in OVCAR-3 (Fig. 4A), A2780 (Fig. 4B) and PC-3 (Fig. 4C) cells.
Similarly, HIF-1α overexpression had no effect on COX-2 mutant reporter activity in any of the
cell lines tested (Figs. 4D-F). From these data we conclude that HIF-1α regulates COX-2
transcription via the HRE (-576/-584) located in the COX-2 promoter.

Hypoxia regulates COX-2 transcription via HIF-1α expression. To determine if hypoxia
stimulates COX-2 expression at the level of transcription via stabilization of HIF-1α, we cotransfected several cell types with COX-2 reporter and HIF-1α DN. Hypoxia stimulated COX-2
transcriptional activation in all cell types (Figs. 5). Furthermore, inhibition of HIF-1α
completely eliminated this effect in OVCAR-3 (Fig. 5 A), A2780 (Fig. 5 B) and PC-3 (Fig. 5 C)
cells. We also tested A2780 and PC-3 cells stably transfected with either siHIF-1α or HIF-1α
CA for COX-2 transcriptional activity. Expression of siHIF-1α decreased basal and completely
abrogated hypoxia-induced COX-2 transcriptional activity (Figs. 5 D & E). Conversely, cells
stably expressing HIF-1α CA exhibited basal levels of COX-2 transcriptional activity similar to
those of control cells stimulated by hypoxia (Figs. 5 F & G). To determine if the HRE (-576/584) is necessary for hypoxia-induced COX-2 transcriptional activation, we transfected A2780
and PC-3 cells with either the wild type COX-2 reporter or the COX- 2 HRE (-576/-584) mutant
reporter. We then subjected the cells to hypoxia for 24 h and measured luciferase activity.
Hypoxia stimulated COX-2 transcriptional activity in both cell lines transfected with the wild
type COX-2 reporter; furthermore, basal and hypoxia stimulated COX-2 transcriptional activity
was dramatically decreased by the mutation in the HRE (Figs. 5 H & I). We performed similar
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experiments in A2780 and PC-3 cells stably transfected with HIF-1α CA, and found even more
dramatic decreases in COX-2 transcriptional activity due to the HRE mutation (Figs. 5 J & K).
Conversely, A2780 and PC-3 cells stably expressing siHIF-1α exhibited much less difference in
COX-2 transcriptional activity between the wild type promoter and the HRE mutant promoter
(Figs. 5 L & M). Overall, these data indicate that hypoxic induction of COX-2 expression is
dependent upon HIF-1 and a functional HIF-1 DNA binding activity in HRE (-576/-584).

HIF-1 binds the COX-2 promoter in vivo in a hypoxia dependent manner. To ensure that HIF-1
was indeed regulating COX-2 expression directly via interaction with the COX-2 promoter, we
performed chromatin immunoprecipitation (CHiP). A2780 cells were cross-linked with formalin
and subjected to immunoprecipitation with HIF-1α antibody after which DNA fragments could
be collected, purified and used in PCR reactions together with primers flanking either the VEGF
HRE, as a positive control, or the HRE in the COX-2 promoter. In Fig. 6 A, we show that HIF-1
bound the HRE on the VEGF promoter, and that this binding was increased by hypoxia, as
expected. We also show that HIF-1 binds to the COX-2 promoter, and that this binding is further
increased by hypoxia, although not to the levels of VEGF (Fig. 6 B). Thus, HIF-1 directly binds
the COX-2 promoter in vivo at the HRE.

PI3K can regulate COX-2 transcription through HIF-1α. Previously our group and others have
shown that PI3K regulates HIF-1α under a variety of conditions in the cell (44,47). Furthermore,
it has been shown previously that PI3K can regulate COX-2 expression in some cell types
(3,50,55). To determine if PI3K regulates COX-2 expression via HIF-1α, we stimulated A2780
and PC-3 cells stably expressing either HIF-1α CA or siHIF-1α with hypoxia for 8 h in the
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presence or absence of LY294002, a PI3K inhibitor, or PDTC, an NFκB inhibitor. Treatment
with LY294002 greatly decreased COX-2 mRNA expression due to hypoxia in the control group
for both cell lines (Figs. 7 A & B). However, expression of HIF-1α CA partially reversed the
effect of PI3K inhibition on COX-2 mRNA expression (Figs. 7 A & B). Furthermore,
expression of siHIF-1α decreased COX-2 mRNA expression to levels that were not further
decreased by treatment with LY294002 in both cell lines (Figs. 7 A & B). Because NF-κB is
also thought to act downstream of PI3K to regulate COX-2 expression we treated both cell lines
with PDTC, an NF-κB inhibitor. Treatment with PDTC strongly inhibited hypoxic induction of
COX-2 mRNA in the control groups of both cell lines. However, expression of HIF-1α CA
partially reversed this inhibition (Figs. 7 A & B). Furthermore, PDTC had almost no effect on
COX-2 mRNA expression in the cells stably expressing siHIF-1α (Figs. 7 A & B). To determine
if COX-2 protein expression is similarly regulated, we treated A2780 cells stably expressing
HIF-1α CA with a variety of inhibitors under normoxic and hypoxic conditions and performed
immunoblots for HIF-1α and COX-2. We then examined the effects of PI3K and NF-κB
inhibition on hypoxia-induced COX-2 protein expression and found that expression of HIF-1α
CA completely reversed the effects of both inhibitors on hypoxia-induced COX-2 expression
(Fig. 7C). We also found that inhibition of JNK did not decrease and actually slightly increased
hypoxic induction of COX-2 protein in both control and HIF-1α CA expressing cells (Fig. 7D).
From these data we conclude that basal and hypoxia-induced COX-2 expression is mediated by
PI3K via interaction with NF-κB and HIF-1α.

PI3K regulates basal and hypoxia- stimulated COX-2 expression at the transcriptional level
through HIF-1 binding to a functional HRE (-576/-584). We next examined the effects of PI3K
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inhibition on COX-2 transcriptional activity. A2780 cells transfected with siRNA specific for
Akt (siAkt) exhibited a dramatic decrease in COX-2 reporter activity (Fig. 8A), as did cells
treated with LY294002 or PDTC for 24 h (Fig. 8B). Stable expression of siHIF-1α eliminated
the inhibitory effect of LY294002 on COX-2 transcriptional activity and partially abrogated the
effect of PDTC (Figs. 8B). Inhibition of PI3K also reversed hypoxic stimulation of COX-2
reporter activity in both A2780 and PC-3 cells (Figs. 8C & D). Conversely, mutation of the HRE
(-576/-584) partially abrogated the effect of PI3K inhibition on basal and hypoxia-induced COX2 reporter activity (Fig. 8D). From these data we concluded that PI3K regulates basal and
hypoxia-induced COX-2 expression via modulation of HIF-1 transcriptional activity.

DISCUSSION
This study examines the role of HIF-1α in the regulation of COX-2 expression.
Previously it has been shown that HIF-1α and COX-2 expression are both upregulated in cancer
(4,8), and are regulated by many of the same stimuli (14,45) (22,31,51,56). Furthermore, the
COX-2 promoter contains several HREs, one of which we predicted to be functional. Here we
show that HIF-1α regulates COX-2 expression and function both under basal conditions as well
as in response to hypoxia in cancer cells. Furthermore, a functional HRE (-576/-584) in the
COX-2 promoter is required for HIF-1α to stimulate COX-2 expression. Because PGE2, a
product of COX-2 enzymatic activity, has been shown to stimulate HIF-1α expression, this
points to a positive feedback loop, in which COX-2 induction by HIF-1α in hypoxia leads to the
production of PGE2. This event would lead to further stimulation of HIF-1α expression by PGE2
in an autocrine or paracrine manner (Fig . 9). This autocrine signaling loop is not without
precedent. One study has shown that VEGF signals in an autocrine manner, upregulating HIF-
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1α expression and, in turn the expression of VEGFR2 (49). Furthermore, IGF-2 has been shown
to stimulate HIF-1α expression, and is in turn upregulated at the level of transcription by HIF-1
(9). The proposed HIF-1α-COX-2-PGE2 angiogenic cascade would be minimally active in
cancer cells until subjected to hypoxia, which would be the initial signaling event leading to the
stabilization of HIF-1α. Thus, in hypoxic conditions, such as those that prevail in oxygen
deprived tumors, pro-angiogenic factors such as VEGF and PGE2 could stimulate their own
production. This would lead to a positive feedback loop stimulating angiogenesis in tumors as
long as the environment remained hypoxic. This process would be advantageous to developing
tumors which need to produce new blood vessels to grow beyond a small size.
In this study we also investigated the role of PI3K in HIF-1α mediated COX-2
expression. Previously, we and others have shown that PI3K is constitutively active in a variety
of different types of cancer (47,54). Others have indicated that PI3K can regulate COX-2
expression (3,50,55). Here we show a direct link between PI3K signaling and activation of
COX-2 transcription in several different cancer cell lines via HIF-1α expression. Others have
shown that PI3K can mediate COX-2 transcription via NF-κB (3,55), and that hypoxia also
stimulates COX-2 transcription by upregulating NF-κB DNA binding (43). Here we do show
that an inhibitor of NF-κB, PDTC, has an inhibitory effect on COX-2 transcription. However,
this effect was completely reversed by expression of constitutively active HIF-1α and,
furthermore, was lessened in cells with depleted HIF-1α expression. Several studies indicate that
NF-κB can regulate HIF-1α expression downstream of PI3K (10,24,25,60), partially explaining
the results we obtained using an inhibitor of NF-κB. Furthermore, as the HRE in the COX-2
promoter was required for regulation of COX-2 by HIF-1α, we can rule out the possibility that
HIF-1α is regulating COX-2 via a non-specific, non-transcriptional mechanism. Our data and
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previous studies seem to indicate some form of cooperative regulation of COX-2 transcription
between NF-κB and HIF-1α in the cells. Further study is warranted to examine the interaction
between HIF-1α and NF-κB in the regulation of COX-2, and perhaps other common
transcriptional targets of HIF-1α and NF-κB.
In summary, in this study we showed that COX-2 expression in cancer cells under basal
conditions as well as in hypoxia, was dependent upon transcriptional regulation of COX-2 by
HIF-1α. HIF-1-dependent regulation of COX-2 required a functional HRE (-576/-584), and was
regulated by PI3K signaling.
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Figure 1. HIF-1α regulates basal and hypoxia-stimulated PGE2 production, COX-2 protein and
mRNA expression. A, A2780 cells stably expressing either pcDNA3 vector or HIF-1α CA were
cultured in normoxia or hypoxia for 8h. The cells were collected, and HIF-1α, COX-2 and βactin protein expression were analyzed by immunoblot. B, A2780 cells stably expressing either
Control siRNA (siControl) or HIF-1α siRNA (siHIF-1α) were cultured in normoxia or hypoxia
for 8h. The cells were collected and levels of HIF-1α, COX-2 and β-actin protein expression
were analyzed by immunoblotting. C, A2780 cells stably expressing either pcDNA3 vector or
HIF-1α CA were cultured in normoxia or hypoxia for 24h. The conditioned media were
analyzed for PGE2 levels via ELISA. Results were normalized to the cell number and
standardized to that of normoxic control. *—indicates significant difference from normoxic
control (p<0.01). #—indicates significant difference from normoxic cells expressing HIF-1α CA
(p<0.05). D, A2780 cells stably expressing either siControl or siHIF-1α were cultured in
normoxia or hypoxia for 24h. The conditioned media was analyzed for PGE2 levels via ELISA.
Results were normalized to the cell number and standardized to that of normoxic control. *—
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indicates significant difference from normoxic control (p<0.05). #—indicates significant
difference from hypoxic control (p<0.05). E, PC-3 cells stably expressing either pcDNA3 vector
or HIF-1α CA were cultured in normoxia or hypoxia for 8h. The cells were collected and levels
of HIF-1α, COX-2 and β-actin protein expression were analyzed by immunobloting. F, PC-3
cells stably expressing either siControl or siHIF-1α were cultured in normoxia or hypoxia for 8h.
The cells were collected and levels of HIF-1α, COX-2 and β-actin protein expression were
analyzed by immunoblotting. G, PC-3 cells stably expressing either pcDNA3 vector or HIF-1α
CA were cultured in normoxia or hypoxia for 24h. Supernatant was collected and analyzed for
PGE2 expression. Values were normalized to the cell number and standardized to that of
normoxic control. *—indicates significant difference from normoxic control (p<0.05). #—
indicates significant difference from hypoxic cells (p<0.05). H, PC-3 cells stably expressing
either siControl or siHIF-1α were cultured in normoxia or hypoxia for 24h. Supernatant was
collected and analyzed for PGE2 expression. Values were normalized to the cell number and
standardized to that of normoxic control. *—indicates significant difference from normoxic
control (p<0.05). #—indicates significant difference from normoxic cells expressing siHIF-1α
(p<0.05). I, A2780 cells stably expressing siHIF-1α or HIF-1α CA were cultured in normoxia
or hypoxia for 8h. COX-2 mRNA was measured using Real-time RT-PCR as described in
Materials and Methods and values were normalized to GAPDH. J, Representative results of the
above experiment measured via qualitative RT-PCR. 18S mRNA served as an internal control.
K, PC-3 cells stably expressing siHIF-1α or HIF-1α CA were cultured in normoxia or hypoxia
for 8h. COX- 2 mRNA was measured using Real-time RT-PCR as described in Materials and
Methods. GAPDH served as an internal control. L, Representative results of the above
experiment analyzed via Qualitative RT-PCR. 18S mRNA served as an internal control.
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Figure 2. HIF-1α does not regulate PMA-induced COX-2 activity A, A2780 cells stably
expressing either pcDNA3 vector or HIF-1α CA were stimulated with 100nM PMA for the
indicated time periods. The cells were collected and levels of HIF-1α, COX-2 and β-actin
protein expression were analyzed by immunoblotting. B, A2780 cells stably expressing either
pcDNA3 vector or HIF-1α CA were stimulated with the indicated doses of PMA for 8 h. The
cells were collected and levels of HIF-1α, COX-2 and β-actin protein expression were analyzed
by immunoblotting. C, PC-3 cells stably expressing pcDNA3 or HIF-1α CA were treated with
the indicated doses of PMA for 8h. Levels of HIF-1α, COX-2 and β-actin protein expression
were analyzed by immunoblotting. D, A2780 cells stably expressing siControl or siHIF-1α were
treated with 100 nM PMA for the indicated times. Levels of HIF-1α, COX-2 and β-actin protein
expression were analyzed by immunoblotting. E, A2780 cells stably expressing siControl or
siHIF-1α were treated the indicated doses of PMA for 8h. Levels of HIF-1α, COX-2 and β-actin
protein expression were analyzed by immunoblotting. F, PC-3 cells stably expressing siControl
or siHIF-1α were treated with the indicated doses of PMA for 8h. Levels of HIF-1α, COX-2 and
β-actin protein expression were analyzed by immunoblotting. G, A2780 cells stably expressing
siHIF-1α or HIF-1α CA were treated with PMA for 4h. COX-2 mRNA was measured using
Real-time RT-PCR as described in Materials and Methods. GAPDH served as an internal
control. *—indicates significant difference from normoxic vector expressing control (p<0.05).
H, Representative results of the above experiment analyzed via qualitative RT-PCR. 18S mRNA
served as an internal control. I, A2780 cells stably expressing pcDNA3 or HIF-1α CA were
pretreated with PDTC, an NF-κB inhibitor and SP600125, a JNK inhibitor, for 30 min prior to
stimulation with PMA (100nM) for 8 h. HIF-1α, COX-2 and β-actin protein expression were
analyzed by immunoblotting.
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Figure 3. HIF-1α expression controls COX-2 transcriptional activity. To assay the COX-2
transcriptional activiation, OVCAR3 and A2780 ovarian cancer cells and PC-3 prostate cancer
cells were co-transfected with a COX-2 reporter containing the functional COX-2 promoter
coupled to firefly luciferase (COX-2/LUC) and a pCMV-βgal plasmid. Relative luciferase
activity was determined by the ratio of luciferase:β-gal activity and normalized to the control.
*—indicates significant difference from normoxic control (p<0.05). A and B, OVCAR-3 cells
transfected with COX-2 reporter and either HIF-1α CA (A) and HIF-1α WT (B). C, A2780 cells
transfected with COX-2 reporter and HIF-1α WT. D, PC-3 cells transfected with COX-2
reporter and HIF-1α WT. E and F, OVCAR-3 cells transfected with COX-2 reporter and either
HIF-1α DN (E) or siHIF-1α (F). G and H, A2780 cells transfected with COX-2 reporter and
either HIF-1α DN (G) or siHIF-1α (H). I and J, PC-3 cells transfected with COX-2 reporter and
either HIF-1α DN (I) or siHIF-1α (J).
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Figure 4. HIF-1 DNA binding is necessary for HIF-1α to regulate COX-2 transcriptional
activity. OVCAR-3 and A2780 ovarian cancer cells and PC-3 prostate cancer cells were cotransfected a COX-2 reporter containing the functional COX-2 promoter with a 3 bp substituition
in the HRE rendering HIF-1 unable to bind, coupled to firefly luciferase (COX2 MUT/LUC),
and a pCMV-βgal plasmid. Relative luciferase activity was determined by the ratio of luciferase
to β-gal activity and normalized to the control. *—indicates significant difference from
normoxic control (p<0.05). A, OVCAR-3 cells were transfected with COX-2 mutant reporter
and the indicated concentrations of HIF-1α DN. B, A2780 cells were transfected with COX-2
mutant reporter and the indicated concentrations of HIF-1α DN. C, PC-3 cells were transfected
with COX-2 mutant reporter and the indicated concentrations of HIF-1α DN. D, OVCAR-3 cells
were transfected with COX-2 mutant reporter and the indicated concentrations of HIF-1α WT.
E, A2780 cells were transfected with COX-2 mutant reporter and the indicated concentrations of
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HIF-1α WT. F, PC-3 cells were transfected with COX-2 mutant reporter and the indicated
concentrations of HIF-1α WT.
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Figure 5. Hypoxic upregulation of COX-2 reporter activity requires HIF-1 binding to a
functional HRE (-576/-584) in the COX-2 promoter. OVCAR-3 (A), A2780 (B) and PC-3 (C)
cells were transfected with either HIF-1α dominant negative or empty vector and COX-2 reporter
then exposed to hypoxia for 24 h prior to collection. *—indicates significant difference from
normoxic control (p<0.05). #—indicates significant difference from cells cultured in hypoxia
(p<0.05). D, A2780 cells stably expressing siControl or siHIF-1α were transfected with COX-2
reporter then cultured in normoxia or hypoxia for 24 h prior to collection. *—indicates
significant difference from normoxic control (p<0.05). #—indicates significant difference from
normoxic cells expressing siHIF-1α (p<0.05). E, PC-3 cells stably expressing either siControl or
siHIF-1α were transfected with COX-2 reporter and cultured in normoxia or hypoxia for 24 h
prior to collection. *—indicates significant difference from normoxic control (p<0.05). #—
indicates significant difference from normoxic cells expressing siHIF-1α (p<0.05). F, A2780
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cells stably expressing either pcDNA3 or HIF-1α CA were transfected with COX-2 reporter and
cultured in normoxia or hypoxia for 24 h prior to collection. *—indicates significant difference
from normoxic control (p<0.05). #—indicates significant difference from normoxic cells
expressing HIF-1α CA (p<0.05). G, PC-3 cells stably expressing either pcDNA3 or HIF-1α CA
were transfected with COX-2 reporter and cultured in normoxia or hypoxia for 24 h prior to
collection. *—indicates significant difference from normoxic control (p<0.05). #—indicates
significant difference from normoxic cells expressing HIF-1α CA (p<0.05). H, A2780 cells
were transfected with either COX-2/LUC or COX-2 MUT/LUC, then cultured in normoxia or
hypoxia for 24h. *—indicates significant difference from normoxic control COX-2/LUC
(p<0.05). #—indicates significant difference from normoxic cells expressing COX2MUT/LUC
(p<0.05). I, PC-3 cells were transfected with either COX-2/LUC or COX-2 MUT/LUC then
cultured in normoxia or hypoxia for 24h. *—indicates significant difference from normoxic
control COX-2/LUC) (p<0.05). #—indicates significant difference from normoxic cells
expressing COX2MUT/LUC. J, A2780 cells stably expressing pcDNA3 or HIF-1α CA
transfected with either COX-2/LUC or COX-2 MUT/LUC, then cultured in normoxia or hypoxia
for 24h. *—indicates significant difference from normoxic control COX-2/LUC (p<0.05). #—
indicates significant difference from normoxic cells expressing COX2MUT/LUC. K, A2780
cells stably expressing siControl or siHIF-1α were transfected with either COX-2/LUC or COX2 MUT/LUC, then cultured in normoxia or hypoxia for 24h. *—indicates significant difference
from normoxic control COX-2/LUC (p<0.05). #—indicates significant difference from
normoxic cells expressing COX2MUT/LUC. L, PC-3 cells stably expressing pcDNA3 or HIF1α CA were transfected with either COX-2/LUC or COX-2 MUT/LUC, then cultured in
normoxia or hypoxia for 24h. *—indicates significant difference from normoxic control COX-
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2/LUC (p<0.05). #—indicates significant difference from normoxic cells expressing
COX2MUT/LUC. K, PC-3 cells stably expressing siControl or siHIF-1α were transfected with
either COX-2/LUC or COX-2 MUT/LUC, then cultured in normoxia or hypoxia for 24h.
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Figure 6. HIF-1α binds the COX-2 promoter in A2780 cells in a hypoxia-dependent manner. A,
A2780 cells were cultured for 8h in normoxia or hypoxia, then crosslinked with formalin,
sonicated and immunoprecipitated with HIF-1α antibody as described in Materials and Methods.
Real-time PCR results are normalized to 10% input control. The VEGF promoter sequence was
amplified in these experiments using primers that flank the putative HRE in the VEGF promoter
to determine the efficacy of our technique. The data shown are the results of three separate
experiments. B, A2780 cells were cultured for 8h in hypoxia, then crosslinked with formalin,
sonicated and immunoprecipitated with HIF-1α antibody as described in Materials and Methods.
Real-time PCR results are normalized to 10% input control. The COX-2 promoter sequence was
amplified using primers that flank the HRE (-576/-584). The data shown are the results of three
separate experiments.
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Figure 7. Inhibition of PI3K and NF-κB inhibits COX-2 mRNA and protein expression in a HIF1α dependent manner. A and B, A2780 (A) and PC-3 (B) cells stably expressing siHIF-1α or
HIF-1α CA were pretreated for 30min with the indicated inhibitors, then cultured in normoxia or
hypoxia for 8h. mRNA was measured using Real-time RT-PCR as described in Materials and
Methods. *—indicates significant difference from normoxic vector control (p<0.05). #—
indicates significant difference from vector-expressing cells subjected to hypoxia (p<0.05). C,
A2780 cells stably expressing PCDNA 3 or HIF-1α CA were treated as above. Levels of HIF1α, COX-2 and β-actin protein expression were analyzed by immunoblotting. D and E. A2780
cells stably expressing HIF-1α CA were pretreated with the indicated drugs for 30 min, and then
cultured in normoxia or hypoxia for 8h. Levels of HIF-1α, COX-2 and β-actin protein
expression were analyzed by immunoblotting.
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Figure 8. PI3K regulates COX-2 transcription through HIF-1α and the predicted HRE (-576/584) in the COX-2 promoter. COX-2 transcriptional activity was measured as described above
using COX-2/LUC. A, A2780 cells were co-transfected with COX2/LUC and siRNA specific
for Akt (siAkt). *—indicates significant difference from control (p<0.05). B, A2780 cells stably
expressing either siControl or siHIF-1α were transfected with COX2/LUC, and then treated with
the indicated doses of the PI3 kinase inhibitor, LY294002 or the NF-κB inhibitor, PDTC. *—
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20

indicates significant difference from control (p<0.05). #—indicates significant difference from
cells expressing HIF-1α (p<0.05). C, A2780 cells were transfected with COX2/LUC, pre-treated
with LY294002 for 30 min, then cultured in normoxia or hypoxia for 24h. *—indicates
significant difference from normoxic control (p<0.05). #—indicates significant difference from
cells cultured in hypoxia (p<0.05). D, PC-3 cells were transfected with COX2/MUT, pretreated
with LY294002 for 30 min, then cultured in normoxia or hypoxia for 24h. *—indicates
significant difference from normoxic control (p<0.05). #—indicates significant difference from
cells cultured in normoxia or hypoxia (p<0.05). E, A2780 cells were transfected with COX-2
MUT/LUC, pre-treated with LY294002, then cultured in normoxia or hypoxia for 24h. #—
indicates significant difference from cells exposed to hypoxia (p<0.05).
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Figure 9. Proposed HIF-1—COX2—PGE2 positive feed-back loop. Hypoxia triggers HIF-1α
stabilization in a tumor, which induces the expression of pro-angiogenic factors, such as VEGF
and PGE2 are released. These secreted factpors could, in turn, act in an autocrine or paracrine
fashion to stimulate HIF-1α expression, leading to even greater levels of angiogenesis within a
tumor in areas of hypoxia.
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CHAPTER 6: GENERAL SUMMARY AND CONCLUSIONS
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The studies performed for this dissertation seek to understand the role of HIF-1α in
human cancer using ovarian and prostate cancer cells as model systems. Initially we wanted to
study the mechanism by which HIF-1α is over-expressed in the absence of stimuli in cancer cells
with activated PI3K/Akt signaling. We found that PI3K/Akt was regulating HIF-1α expression
via two distinct targets, p70S6K1 and hdm2. Similarly, Bardos et al. showed that PI3K regulates
growth factor stimulation of HIF-1α expression at the level of translation rate via HDM2 (6).
Furthermore, one of our collaborators has shown that HIF-1α and Mdm2 interact physically in a
p53-independent manner (74). This interaction was shown to activate HIF-1α and HIF-1
transcriptional activity, which is consistent with our results (74). These data suggest that PI3K
controls HIF-1α expression and HIF-1 dependent transcription at several levels.
After examining the mechanism by which basal expression of HIF-1α is upregulated in
cancer cells by activation of PI3K signaling, we wanted to determine if this effect had
physiological significance. To do this, we generated cancer cells that stably expressed siRNA
specific to HIF-1α (siHIF-1α) and examined the characteristics of these cells. In chapter 3, we
observed that cells expressing siHIF-1α exhibited decreased motility and invasion. Furthermore,
tumors generated from cells expressing siHIF-1α exhibited dramatically different behavior based
upon their microenvironment. In an avascular microenvironment, inhibition of HIF-1α
expression by siRNA dramatically decreased tumor size and angiogenesis. Conversely, in a
subcutaneous microenvironment which has a pre-existing microvasculature, inhibition of HIF-1
slightly increased tumor size with no visible effect on angiogenesis. During the preparation of
this work, another study found that vascularity of the microenvironment also dramatically
affected the role of HIF-1α in glioblastoma (12). These results have significant implications for
tumor therapy. Currently, several HIF-1α inhibitors are in clinical trials for a variety of different
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types of cancer. Our data and the study mentioned previously indicate that the efficacy of these
treatments will depend on the microenvironment of the tumor being treated.
In chapter 4, we further investigate the role of HIF-1α in cancer. In this study we showed
that chemotherapy inhibited HIF-1α, and that inhibition of HIF-1α expression led to increased
sensitivity to chemotherapy in ovarian and prostate cancer cells. Furthermore, forced expression
of an active form of HIF-1α led to increased chemoresistance. It is well established that hypoxia
can contribute chemotherapy resistance in cancer (41). Bid, a pro-apoptotic member of the Bcl2
family, is also down-regulated by HIF-1α expression and has been linked to resistance to
chemotherapy (32). It has been shown that p-glycoprotein, the product of the multi-drug
resistance gene, is upregulated by hypoxia through HIF-1α expression (22). Here we show
functional evidence linking chemoresistance and HIF-1α expression levels in ovarian and
prostate cancer. Our data indicate that inhibition of HIF-1α expression will be advantageous as
an adjunct to conventional chemotherapy in the treatment of human cancer.
In the final chapter, we found that COX-2 is a novel transcriptional target of HIF-1α in
human cancer. COX-2 is a potent inducer of angiogenesis via its secreted products PGE2 and
TXA. It is also upregulated by many of the stimuli that also affect HIF-1α expression such as
growth factors, oncogenes and hypoxia (27). However, previous data indicated that the observed
upregulation of COX-2 expression in hypoxia is mediated by NF-κB (92). Our data do not rule
out a role for NF-κB in regulating COX-2 transcription, but we show that the primary mediator
of COX-2 transcriptional activity in cancer is mediated by HIF-1α. Because PGE2, a product of
COX-2 enzymatic activity, can increase the expression of HIF-1α we proposed a possible
autocrine or paracrine positive feedback loop connecting HIF-1α and COX-2 (Ch. 5, Figs. 9) in
which hypoxia triggers HIF-1α expression and HIF-1 mediated transcriptional activation of
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COX-2. This leads to increased PGE2 production which further stimulates HIF-1α expression.
This positive feedback loop would be essential in the early development of a tumor, when the
tumor requires angiogenesis for growth. Even a low level of hypoxia would be sufficient to
drive angiogenesis, rendering the tumor even more sensitive to decreased blood flow.
Overall we have shown that PI3K-mediated HIF-1α expression plays a crucial role in
ovarian cancer, not only because of its effects on angiogenesis, but also due to an effect on other
negative measures of clinical outcome, such as invasiveness and chemotherapy resistance.
Furthermore, our data also indicates, with several caveats, that HIF-1α will be a good target for
clinical therapy, particularly in combination with conventional chemotherapy.
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